NZ627272B2 - A combination therapy for a stable and long term engraftment - Google Patents
A combination therapy for a stable and long term engraftment Download PDFInfo
- Publication number
- NZ627272B2 NZ627272B2 NZ627272A NZ62727212A NZ627272B2 NZ 627272 B2 NZ627272 B2 NZ 627272B2 NZ 627272 A NZ627272 A NZ 627272A NZ 62727212 A NZ62727212 A NZ 62727212A NZ 627272 B2 NZ627272 B2 NZ 627272B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cell
- cells
- subject
- dose
- body weight
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title description 4
- 230000003394 haemopoietic Effects 0.000 claims abstract description 135
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 117
- 229960004397 Cyclophosphamide Drugs 0.000 claims abstract description 113
- 238000002054 transplantation Methods 0.000 claims abstract description 97
- 210000001519 tissues Anatomy 0.000 claims abstract description 88
- 239000003814 drug Substances 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 210000004027 cells Anatomy 0.000 claims description 572
- 230000037396 body weight Effects 0.000 claims description 104
- 108090001123 antibodies Proteins 0.000 claims description 102
- 102000004965 antibodies Human genes 0.000 claims description 102
- 210000001185 Bone Marrow Anatomy 0.000 claims description 62
- 108060001251 CD34 Proteins 0.000 claims description 55
- 102100016492 CD34 Human genes 0.000 claims description 55
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 46
- 230000003750 conditioning Effects 0.000 claims description 42
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 27
- 230000002829 reduced Effects 0.000 claims description 24
- 230000003211 malignant Effects 0.000 claims description 22
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 230000000735 allogeneic Effects 0.000 claims description 19
- 230000001143 conditioned Effects 0.000 claims description 19
- 210000003491 Skin Anatomy 0.000 claims description 17
- 210000000056 organs Anatomy 0.000 claims description 17
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 16
- 210000004185 Liver Anatomy 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 229960000390 fludarabine Drugs 0.000 claims description 14
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 14
- 206010025310 Other lymphomas Diseases 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000001400 myeloablative Effects 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 11
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 10
- 210000004072 Lung Anatomy 0.000 claims description 10
- 210000002216 Heart Anatomy 0.000 claims description 9
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims description 9
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 9
- 201000005787 hematologic cancer Diseases 0.000 claims description 9
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 101700087100 CD19 Proteins 0.000 claims description 8
- 102100005826 CD19 Human genes 0.000 claims description 8
- 206010024324 Leukaemias Diseases 0.000 claims description 8
- 108090000393 Muromonab-CD3 Proteins 0.000 claims description 8
- 210000000496 Pancreas Anatomy 0.000 claims description 8
- 230000001154 acute Effects 0.000 claims description 8
- 230000001494 anti-thymocyte Effects 0.000 claims description 8
- 210000003734 Kidney Anatomy 0.000 claims description 7
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 7
- 201000009251 multiple myeloma Diseases 0.000 claims description 7
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 6
- 241000229754 Iva xanthiifolia Species 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 6
- 210000002798 bone marrow cell Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000002406 genetic disease Diseases 0.000 claims description 6
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 6
- 206010002967 Aplastic anaemia Diseases 0.000 claims description 5
- 210000004700 Fetal Blood Anatomy 0.000 claims description 5
- 229960002092 busulfan Drugs 0.000 claims description 5
- 201000010874 syndrome Diseases 0.000 claims description 5
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 4
- 229960001196 Thiotepa Drugs 0.000 claims description 4
- 230000001684 chronic Effects 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- 206010002449 Angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 3
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 3
- 206010009839 Coeliac disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 201000004779 Graves' disease Diseases 0.000 claims description 3
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 3
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 3
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 claims description 3
- 210000000936 Intestines Anatomy 0.000 claims description 3
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 3
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 3
- 201000003791 MALT lymphoma Diseases 0.000 claims description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 3
- 208000002865 Osteopetrosis Diseases 0.000 claims description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 3
- 230000001919 adrenal Effects 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 3
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 claims description 2
- 206010043554 Thrombocytopenia Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006288 alpha thalassemia Diseases 0.000 claims description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000011442 metachromatic leukodystrophy Diseases 0.000 claims description 2
- 230000003393 splenic Effects 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 4
- 230000000527 lymphocytic Effects 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010068051 Chimerism Diseases 0.000 description 29
- 206010018651 Graft versus host disease Diseases 0.000 description 26
- 208000009329 Graft vs Host Disease Diseases 0.000 description 26
- 210000004369 Blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 21
- 230000035492 administration Effects 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 210000004698 Lymphocytes Anatomy 0.000 description 13
- 102100006435 CSF3 Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 230000002354 daily Effects 0.000 description 9
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 8
- 210000000952 Spleen Anatomy 0.000 description 8
- 230000005291 magnetic Effects 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 7
- 206010052779 Transplant rejections Diseases 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 7
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002489 hematologic Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 108010001645 Rituximab Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108091006028 chimera Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000069 prophylaxis Effects 0.000 description 6
- 229960004641 rituximab Drugs 0.000 description 6
- 101710002920 tcrA Proteins 0.000 description 6
- 230000003442 weekly Effects 0.000 description 6
- 102100013077 CD4 Human genes 0.000 description 5
- 101700022938 CD4 Proteins 0.000 description 5
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 5
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 5
- 238000007800 T cell depleted bone marrow transplantation Methods 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
- 210000001772 Blood Platelets Anatomy 0.000 description 4
- 229940109239 Creatinine Drugs 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 108010029961 Filgrastim Proteins 0.000 description 4
- 229960004177 Filgrastim Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000002559 cytogenic Effects 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 201000008286 diarrhea Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000001052 transient Effects 0.000 description 4
- 102100001249 ALB Human genes 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 206010008943 Chronic leukaemia Diseases 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 229960002963 Ganciclovir Drugs 0.000 description 3
- 241000282619 Hylobates lar Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100007544 NCAM1 Human genes 0.000 description 3
- 101700077124 NCAM1 Proteins 0.000 description 3
- 210000000440 Neutrophils Anatomy 0.000 description 3
- 210000002747 Omentum Anatomy 0.000 description 3
- 210000003240 Portal Vein Anatomy 0.000 description 3
- 229960000856 Protein C Drugs 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 102100019730 TP53 Human genes 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 230000003187 abdominal Effects 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940050528 albumin Drugs 0.000 description 3
- 230000000919 anti-host Effects 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000001506 immunosuppresive Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 108060005018 mobB Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000005962 mycosis fungoide Diseases 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- -1 ALT Proteins 0.000 description 2
- 102000009914 Adenosine deaminases Human genes 0.000 description 2
- 108091022188 Adenosine deaminases Proteins 0.000 description 2
- 229940091292 Alo Drugs 0.000 description 2
- 101710027071 B3GAT1 Proteins 0.000 description 2
- 102100018910 B3GAT1 Human genes 0.000 description 2
- 206010060945 Bacterial infection Diseases 0.000 description 2
- 210000000601 Blood Cells Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 2
- 102100008191 CD8A Human genes 0.000 description 2
- 101700054655 CD8A Proteins 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 101700051117 FUT1 Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 206010018048 Gaucher's disease Diseases 0.000 description 2
- 210000003714 Granulocytes Anatomy 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010068202 Leukodystrophy Diseases 0.000 description 2
- 206010024381 Leukodystrophy Diseases 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- 206010028417 Myasthenia gravis Diseases 0.000 description 2
- 241001494457 Nemia Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 206010033775 Paraesthesia Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000002491 Severe Combined Immunodeficiency Diseases 0.000 description 2
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 206010068760 Ulcers Diseases 0.000 description 2
- 210000001325 Yolk Sac Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000843 anti-fungal Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 101710017890 large T Proteins 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000877 morphologic Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003533 narcotic Effects 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000004923 pancreatic tissues Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002992 thymic Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101710026914 AAG Proteins 0.000 description 1
- 229940092117 ATGAM Drugs 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229940086848 Allopurinol 300 MG Drugs 0.000 description 1
- 229940009444 Amphotericin Drugs 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 241000349774 Bikinia letestui Species 0.000 description 1
- 208000002352 Blister Diseases 0.000 description 1
- 230000037227 Blood Loss Effects 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010064913 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 229940112133 Busulfex Drugs 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000000350 Central Nervous System Disease Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000002573 Connective Tissue Disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N Foscarnet Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000008384 Ileus Diseases 0.000 description 1
- 210000001822 Immobilized Cells Anatomy 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 208000007906 Intestinal Disease Diseases 0.000 description 1
- 210000003810 Killer Cells, Lymphokine-Activated Anatomy 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 101710015344 LNPEP Proteins 0.000 description 1
- 229940047834 Lemtrada Drugs 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 208000002490 Leukemia, Myelomonocytic, Juvenile Diseases 0.000 description 1
- 208000000748 Leukemia, Prolymphocytic, T-Cell Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- 210000004287 Lymphocytes, Null Anatomy 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 210000004086 Maxillary Sinus Anatomy 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229940090009 Myleran Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 206010034754 Petechiae Diseases 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037175 Psychiatric disease Diseases 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000379147 Strawberry green petal phytoplasma Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 208000000389 T-Cell Leukemia Diseases 0.000 description 1
- 206010042985 T-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 210000000115 Thoracic Cavity Anatomy 0.000 description 1
- 229940107955 Thymoglobulin Drugs 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 240000000913 Typha elephantina Species 0.000 description 1
- 235000018747 Typha elephantina Nutrition 0.000 description 1
- 210000003954 Umbilical Cord Anatomy 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000003558 Zoonosis Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 231100000429 cutaneous necrosis Toxicity 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000010770 muscular disease Diseases 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 210000000773 pre-NK cell Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 108010056900 thymoglobulin Proteins 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 230000002618 waking Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Disclosed is the use of a dose of T cell depleted immature hematopoietic cells and a therapeutically effective amount of cyclophosphamide in the manufacture of a medicament for treating a subject in need of a non-syngeneic cell, tissue graft or immature hematopoietic cell transplantation.
Description
A COMBINATION THERAPY FOR A STABLE AND LONG TERM
TMENT
RELATED APPLICATION/S
US. Provisional Patent Application No. ,917 filed on December 22, 2011,
which is hereby incorporated by reference as if fully set forth herein.
FIELD AND BACKGROUND OF THE INVENTION
The present ion, in some embodiments thereof, relates to a combination
therapy for attaining a stable and long term cell or tissue transplantation.
The use of full—haplotype mismatched haploidentical donors as an alternative
source for hematopoietic stem cell transplantation (HSCT) is highly attractive since
virtually all patients have a readily available haploidentical family member that can
serve as an HSCT donor. Early ts to avoid fatal graft versus host disease (GVHD)
risk and to apply haploidentical rigorously T cell depleted bone marrow transplantation
(TDBMT) in leukemia patients revealed that the absence of donor T cells within the
graft leads to a high rate of graft rejection, mediated by residual radiotherapy and
chemotherapy ant host—derived T cells (HTC). To overcome this obstacle, a ’mega
dose’ of TDBM cells was contemplated which can overcome this HTC mediated
immune barrier and be engrafted successfully even when using fully mismatched
murine strain combinations [Bachar-Lustig E et al., Nat Med. (1995) 1:1268—1273].
Subsequently, it was demonstrated that in humans, as in rodents, CD34+ hematopoietic
stem cell dose escalation may be used to overcome genetic barriers, enabling
satisfactory survival rates ing purified haploidentical HSCT [Reisner Y and
Martelli ME. Immunol Today. (1995) -440 and US. Patent No. 5,806,529].
While the use of a purified ’mega dose’ of CD34+ HSCT has enabled
haploidentical transplantation in leukemia patients, one major drawback, common to all
T cell ed transplants, is the slow recovery rate of the recipient’s immune .
This is attributed to ive immune ablating conditioning protocols prior to
transplantation, the low numbers of donor T cells infused within the graft and to the
decreased thymic function of adult recipients. Thus, in adult recipients of a
haploidentical CD34+ stem cell graft, a significant rate of transplant d mortality
(TRM) is caused by opportunistic infections.
Several approaches are being developed to address this challenge. This includes
novel modalities to improve thymic function, post—transplant ve transfer of anti-
viral specific T cells, transfer of partially polyclonal host—non—reactive allo-depleted T
cells or transfer of fully polyclonal T cells transfected with inducible e genes. An
alternative and additional approach to preserve host immunity is the use of reduced
intensity ioning (RIC). This non-myeloablative approach spares a substantial
level of host immune cells and thus may reduce TRM by both improving post—transplant
immune reconstitution and reducing the toxicity associated with the conditioning
agents. Haploidentical transplantation under RIC is even more intricate due to the
substantial immunological barrier presented by the surviving host T cells. Recent
attempts to overcome this barrier, largely made use of non—T cell depleted grafts, which
enable a high rate of engraftment, but in the expanse of increased rates of GVHD.
Another ch for applying haploidentical transplantation under RIC uses
CD3/CD19 depleted grafts, which not only contain CD34+ stem cells but also CD34
negative progenitors, NK, graft facilitating cells and dendritic cells, however, this too is
at the expanse of increased rates of GVHD and TRM.
In the 1970’s George Santos demonstrated in rodents that a short course of high—
dose cyclophosphamide (CY) soon after bone marrow transplant (BMT) targeted
activated donor or host active T cells [Owens AH Jr and GW. S. Transplantation.
(1971) 11:378—382]. Cyclophosphamide was observed to be non—toxic to hematopoietic
stem cells e of their high expression of the detoxifying enzyme de
dehydrogenase, and Slavin et al. further demonstrated that administration of high dose
hosphamide can reduce GVHD and graft rejection in mice, without adverse
ix.) LII effects on stem cell engraftment [Brodsky RA and R]. J. Lancet. (2005) 365:1647—
1656]. Clinical trials by the John s and Fred Hutchinson Cancer Research
Center groups, evaluated a non-myeloablative protocol of cyclophosphamide,
abine and ZGy TBI, and post~transplant GVHD prophylaxis With
hosphamide (50 mg/kg days +3 and +4), MMF (days +5 to +35) and tacrolimus
(days +5 to +180) [Luznik L et al., Biology of blood and marrow transplantation:
l of the American Society for Blood and Marrow Transplantation. (2008)
14:641]. According evident from their teachings, this protocol resulted in a high relapse
rate, which was probably due to poor disease debulking by the non-myeloablative
conditioning and to lack of GVHD related graft versus ia (GVL) effect [Munchel
A et al., ric Reports (2011) 3:43—47].
Additional ches for achieving stable engraftment of allogeneic
poietic stem cells have been attempted, some are described in U.S. Patent
Application No. 10909, U.S. Patent Application No. 18142, U.S. Patent
Application No. 20070098693, U.S. Patent No. 5,876,692, U.S. Patent No. 5,514,364,
U.S. Patent No. 6,217,867, U.S. Patent No. 5,635,156, U.S. Patent Application No.
20060140912, U.S. Patent Application No. 20040005300, U.S. Patent Application No.
41027, U.S. Patent Application No. 20030017152, U.S. Patent Application No.
20030165475 and U.S. Patent Application No. 20010009663.
SUMMARY OF THE ION
In a first aspect of the invention there is provided the use of a dose of T cell
depleted immature hematopoietic cells, wherein said T cell depleted immature
hematopoietic cells comprise less than 5 X 105 CD3+ cells per kilogram body weight of a
subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram
body weight of the subject, and a therapeutically effective amount of cyclophosphamide,
wherein said therapeutically effective amount comprises 25—200 mg per kilogram body
weight of the subject, and wherein said cyclophosphamide is for administration to the
subject following transplantation of a cell or tissue graft, in the manufacture of a
medicament for treating a subject in need of a non-syngeneic cell or tissue graft, wherein
said subject has a malignant disease.
In another aspect of the present invention there is provided the use of a dose of T
cell depleted immature hematopoietic cells, wherein said T cell depleted immature
hematopoietic cells comprise less than 5 x 105 CD3+ cells per kilogram body weight of a
subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram
body weight of the subject, and a therapeutically ive amount of cyclophosphamide,
wherein said therapeutically effective amount comprises 25-200 mg per am body
weight of the subject, and wherein said hosphamide is for administration to the
subject following transplantation of a cell or tissue graft, in the manufacture of a
(followed by page 3a)
medicament for treating a subject in need of a non-syngeneic cell or tissue graft, wherein
said subject has a non-malignant disease.
In a further aspect of the invention there is provided the use of a dose of T cell
depleted immature poietic cells, wherein said T cell depleted immature
hematopoietic cells comprise less than 5 X 105 CD3+ cells per kilogram body weight of a
subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram
body weight of the subject, and a therapeutically effective amount of cyclophosphamide,
wherein said therapeutically effective amount comprises 25—200 mg per kilogram body
weight of the subject, and wherein said cyclophosphamide is for administration to the
subject following transplantation of immature hematopoietic cells in the manufacture of a
medicament for treating a conditioned subject in need of an re hematopoietic cell
transplantation, and wherein said subject has a malignant disease .
In a still r aspect of the invention there is provided the use of a dose of T cell
depleted immature poietic cells, wherein said T cell depleted immature
hematopoietic cells se less than 5 x 105 CD3+ cells per kilogram body weight of a
subject, and wherein said dose comprises at least about 5 X 106 CD34+ cells per kilogram
body weight of the subject, and a therapeutically effective amount of hosphamide,
wherein said therapeutically effective amount comprises 25-200 mg per kilogram body
weight of the t, and wherein said cyclophosphamide is for administration to the
subject following transplantation of immature hematopoietic cells in the manufacture of a
medicament for treating a conditioned subject in need of an re hematopoietic cell
transplantation, and n said subject has a nonmalignant disease .
In another aspect of the invention there is provided the use of a reduced intensity
ioning protocol, wherein said reduced intensity conditioning comprises a total body
irradiation (TBI) and a chemotherapeutic agent; a dose of T cell depleted immature
poietic cells, wherein said T cell depleted immature hematopoietic cells comprise
less than 5 x 105 CD3+ cells per kilogram body weight of a t, and wherein said dose
comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject,
and a therapeutically effective amount of cyclophosphamide, wherein said therapeutically
effective amount comprises 25—200 mg per kilogram body weight of the subject, and
wherein said cyclophosphamide is for administration to the subject following
(followed by page 3b)
transplantation of immature hematopoietic cells in the manufacture of a medicament for
ng a subject in need of an immature hematopoietic cell transplantation, and wherein
said subject has a malignant disease.
In yet another aspect of the invention there is provided the use of a reduced
ity conditioning protocol, wherein said reduced intensity conditioning comprises a
total body irradiation (TBI) and a chemotherapeutic agent; a dose of T cell depleted
immature hematopoietic cells, wherein said T cell depleted immature hematopoietic cells
se less than 5 x 105 CD3+ cells per kilogram body weight of a subject, and wherein
said dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the
t; and a therapeutically ive amount of cyclophosphamide, wherein said
therapeutically effective amount comprises 25-200 mg per kilogram body weight of the
subject, and wherein said cyclophosphamide is for administration to the subject following
transplantation of immature hematopoietic cells in the manufacture of a medicament for
treating a subject in need of an immature hematopoietic cell transplantation, and wherein
said subject has a non-malignant disease.
In a still r aspect of the invention there is provided the use of a dose of T cell
depleted immature hematopoietic cells from a non-syngeneic donor, n said T cell
depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ cells per kilogram
body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+
cells per kilogram body weight of the subject; and a therapeutically effective amount of
cyclophosphamide, n said therapeutically ive amount comprises 25—200 mg
per kilogram body weight of the t, and wherein said cyclophosphamide is for
administration to the subject following transplantation of a cell or tissue graft in the
manufacture of a medicament for inducing donor specific tolerance in a subject in need of
a ngeneic cell or tissue graft, wherein said subject has a malignant disease.
In another aspect of the invention there is provided the use of a dose of T cell
depleted immature hematopoietic cells from a non-syngeneic donor, wherein said T cell
depleted re hematopoietic cells comprise less than 5 X 105 CD3+ cells per am
body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+
cells per kilogram body weight of the subject; and a therapeutically effective amount of
cyclophosphamide, wherein said therapeutically effective amount ses 25—200 mg
(followed by page 30)
per kilogram body weight of the subject, and wherein said cyclophosphamide is for
administration to the subject following transplantation of a cell or tissue graft in the
manufacture of a medicament for inducing donor specific tolerance in a t in need of
a ngeneic cell or tissue graft, wherein said subject has a non-malignant disease.
According to an aspect of some embodiments of the present invention there is
provided a method of treating a subject in need of a non—syngeneic cell or tissue graft, the
method comprising: (a) transplanting into a t a dose of T cell depleted immature
hematopoietic cells, n the T cell depleted immature hematopoietic cells comprise
less than 5 x 105 CD3Jr T cells per kilogram body weight of the subject, and wherein the
dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the
subject; and uently (b) administering to the subject a therapeutically effective
amount of cyclophosphamide, n the therapeutically effective amount comprises 25-
200 mg per kilogram body weight, thereby ng the subject.
According to an aspect of some embodiments of the present invention there is
provided a method of treating a subject in need of an immature hematopoietic cell
transplantation, the method comprising: (a) transplanting into a conditioned subject a dose
of T cell depleted re hematopoietic cells, wherein the T cell depleted immature
hematopoietic cells comprise less than 5 x 105 CD3+ T cells per kilogram body weight of
the subject, and wherein the dose ses at least about 5 x 106 CD34+ cells per
kilogram body weight of the subject; and subsequently (b) administering to the subject a
therapeutically effective amount of cyclophosphamide, wherein the therapeutically
effective amount comprises 25-200 mg per kilogram body , thereby treating the
subject.
{FOLLOWED BY PAGE 4]
According to an aspect of some ments of the present invention there is
provided a method of treating a subject in need of an immature hematopoietic cell
transplantation, the method comprising: (a) conditioning a subject under a reduced
ity conditioning protocol, wherein the d intensity conditioning ses a
total body ation (TBI) and a chemotherapeutic agent; (b) transplanting into the
subject a dose of T cell ed immature hematopoietic cells, wherein the T cell
depleted re poietic cells comprise less than 5 X 105 CD3+ T cells per
kilogram body weight of the subject, and wherein the dose ses at least about 5 X
106 CD34+ cells per kilogram body weight of the subject; and subsequently (c)
administering to the subject a eutically effective amount of hosphamide,
wherein the therapeutically effective amount comprises 25~200 mg per kilogram body
weight, thereby treating the subject.
According to an aspect of some embodiments of the present invention there is
provided a method of inducing donor specific tolerance in a subject in need of a non-
eic cell or tissue graft, the method comprising: (a) transplanting into a subject a
dose of T cell depleted re hematopoietic cells obtained from a non-syngeneic
donor, wherein the T cell depleted immature hematopoietic cells comprise less than 5 x
105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose
comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject;
and subsequently (b) administering to the subject a therapeutically effective amount of
cyclophosphamide, wherein the therapeutically effective amount comprises 25~200 mg
per kilogram body weight, thereby inducing donor specific tolerance in the subject.
According to some embodiments of the invention, the method further comprises
conditioning the subject under reduced intensity conditioning prior to step (a).
According to some embodiments of the invention, the method further comprises
conditioning the t with in-vivo T cell debulking prior to step (a).
According to some embodiments of the invention. the dose of the T cell depleted
immature hematopoietic cells comprises 5 - 40 x 106 CD34+ cells per kilogram body
weight of the subject.
According to some embodiments of the invention, the dose of the T cell depleted
immature hematopoietic cells comprises at least about 10 x 106 CD34+ cells per
kilogram body weight of the subject.
WO 93920
According to some embodiments of the invention, the T cell depleted immature
hematopoietic cells are selected from the group consisting of T cell depleted bone
marrow cells, T cell depleted G-CSF mobilized peripheral blood progenitor cells, T cell
depleted cord blood, ed CD34+ cells attained by positive selection from bone
marrow and/or from G—CSF mobilized eral blood progenitor cells, and eX-vivo
expanded CD34+ cells.
According to some embodiments of the invention, the T cell depleted immature
hematopoietic cells comprise less than 1 X 106 CD8+ TCRu/B' cells per kilogram body
weight of the subject.
According to some embodiments of the invention, the T cell depleted immature
hematopoietic cells are obtained by T cell debulking.
According to some embodiments of the invention, the T cell debulking is
effected by antibodies.
According to some embodiments of the ion, the antibodies are selected
from the group consisting of an anti-CD8 antibody, an antinCD4 antibody, an anti—CD3
antibody, an anti—CD2 antibody and an anti-TCRa/B dy.
According to some embodiments of the invention, the antibodies comprise an
anti—CD3 antibody.
ing to some embodiments of the invention, the immature hematopoietic
cells are d by B cell debulking,
According to some embodiments of the invention, the B cell debulking is
effected by an anti—CD19 antibody or by anti—CD20 antibody.
According to some embodiments of the invention, the T cell depleted immature
hematopoietic cells are obtained from a non—syngeneic donor.
According to some embodiments of the invention, the non—syngeneic donor is
allogeneic or xenogeneic with respect to the subject.
According to some embodiments of the invention, the allogeneic donor is
selected from the group consisting of an HLA d sibling, an HLA d
unrelated donor, an HLA haploidentical related donor and a donor displaying one or
more disparate HLA determinants.
According to some embodiments of the invention, the subject is a human subject.
According to some embodiments of the invention, the iii-viva T cell debulking is
effected by antibodies.
ing to some embodiments of the invention, the antibodies comprise an
anti—CD8 dy, an anti—CD4 antibody, or both.
According to some embodiments of the invention, the antibodies comprise anti-
yte in (ATG) dies, anti—CD52 antibodies or anti—CD3 (OKT3)
antibodies.
According to some embodiments of the invention, the reduced ity
conditioning comprises a eloablative conditioning.
According to some embodiments of the invention, the non—myeloablative
conditioning comprises at least one of a total body irradiation (TBI), a total. lymphoid
irradiation (TLI), a chemotherapeutic agent and/or an antibody immunotherapy.
According to some embodiments of the ion, the TBI comprises a single or
fractionated irradiation dose within the range of 1—7.5 Gy.
According to some embodiments of the invention, the TBI comprises a single or
fractionated irradiation dose within the range of 1-3.5 Gy.
According to some embodiments of the invention, the TBI comprises a single or
fractionated irradiation dose within the range of 2 Gy.
ing to some embodiments of the invention, the TBI is effected in a single
dose 2 days prior to step (b).
According to some embodiments of the invention, the herapeutic agent
comprises at least one of Busulfan, Fludarabine, Melphalan and Thiotepa.
According to some ments of the invention, the antibody comprises at least
one of an anti-CD52 antibody, anti—thymocyte globulin (ATG) antibody or anti—CD3
(OKT3) antibody.
According to some embodiments of the invention, the concentration of the
cyclophosphamide is about 100 - 200 mg per kg body weight.
According to some embodiments of the invention, the concentration of the
cyclophosphamide is about 100 mg per kg body weight.
According to some embodiments of the invention, the cyclophosphamide is
administered in a single dose.
WO 93920
According to some embodiments of the invention, the cyclophosphamide is
administered in two doses.
According to some embodiments of the invention, each of the two doses
comprises a concentration of about 50 mg per kg body weight.
According to some embodiments of the invention, each of the two doses is
administered on days 3 and 4 following step (a).
According to some embodiments of the invention, the subject has a malignant
disease.
According to some embodiments of the invention, the malignant disease is a
hematopoietic cancer.
According to some embodiments of the invention, the hematopoietic cancer
comprises a leukemia or lymphoma.
ing to some ments of the invention, the hematopoietic cancer is
selected from the group ting of acute lymphoblastic leukemia (ALL), acute
myelocytic leukemia (AML), acute nonlymphoblastic leukemia (ANLL), Chronic
lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Hodgkin's
Lymphoma, non- Hodgkin's Lymphoma, Extranodal natural killer/T-cell lymphoma,
Cutaneous T—cell lymphoma, Enteropathy type T-cell lymphoma, Angioimmunoblastic
T—cell lymphoma, Anaplastic large T/null—cell lymphoma, Subcutaneous panniculitis-
like T-cell lymphoma, Unspecified T~cell lymphoma, e large B—cell lymphoma, B—
cell chronic lymphocytic leukemia (B—CLL)/chronic lymphoid leukemia (CLL), Chronic
cytic leukemia/small lymphocytic lymphoma, Extranodal marginal zone B—cell
lymphomas - mucosa—associated lymphoid tissue lymphomas, Follicular ma,
Mantle cell ma, Nodal al zone B-cell lymphoma, Burkitt lymphoma,
Hairy cell ia, Primary central nervous system lymphoma, Splenic marginal zone
B—cell lymphoma, plasmocytic lymphoma, Primary mediastinal B-cell
lymphoma and multiple myeloma.
According to some embodiments of the invention, the subject has a non—
malignant disease.
According to some embodiments of the ion, the non-malignant disease is a
genetic disease or disorder, an autoimmune disease or a metabolic disorder.
WO 93920
According to some embodiments of the invention, the non-malignant disease is
selected from the group consisting of sickle cells disease, a congenital neutropenia, a
ocytopenia, an aplastic anemia, a myelodysplastic syndrome, a monosomy 7, an
osteopetrosis, a Gaucher's disease, a Hurler's disease, a romatic leukodystrophy,
an adrenal leukodystrophy, a thalassemia, a congenital or genetically—determined
hematopoietic abnormality, lupus, mune hepatitis, celiac disease, type I diabetes
mellitus, Grave's disease, Guillain—Barr syndrome, Myasthenia gravis, Rheumatoid
arthritis, scleroderma and psoriasis.
According to some embodiments of the invention, the cell or tissue graft
comprises immature hematopoietic cells.
According to some embodiments of the invention, the cell or tissue graft is
selected from the group consisting of a liver, a pancreas, a spleen, a kidney, a heart, a
lung, a skin, an intestine and a lymphoid/hematopoietic tissue or organ.
According to some embodiments of the invention, the cell or tissue graft is
transplanted into the subject prior to, concomitantly with or following the transplanting
the dose of T cell depleted immature hematopoietic cells into the subject.
ing to some embodiments of the ion, the cell or tissue graft
comprises a co—transplantation of several organs.
According to some embodiments of the invention, the cell or tissue graft and the
T cell depleted re poietic cells are obtained from the same donor.
According to some embodiments of the invention, the conditioned subject has
been conditioned under reduced ity conditioning.
According to some embodiments of the invention, the reduced intensity
conditioning is effected l—lO days prior to the transplanting.
ing to some embodiments of the invention, the conditioned subject has
been conditioned with in-vivo T cell debulking.
According to some embodiments of the invention, the in—vivo T cell debulking is
effected 4-7 days prior to the lanting.
ing to some embodiments of the invention, the chemotherapeutic agent
comprises Fludarabine.
According to some embodiments of the invention, the Fludarabine is ed at a
dose of 30 mg/mZ/day.
According to some embodiments of the ion, the Fludarabine is
administered daily on days 3 to 7 prior to step (b).
According to some embodiments of the invention, the T cell depleted immature
hematopoietic cells comprise T cell depleted G—CSF mobilized peripheral blood
itor cells.
It will be appreciated that the present teachings can be used with other tolerance
inducing protocols such as bed in PCT publication Nos. W0 2001/49243, WO
2007/023491 and , which are herein incorporated by reference in their
entirety.
Unless otherwise defined, all cal and/or scientific terms used herein have
the same meaning as ly understood by one of ordinary skill in the art to which
the invention pertains. Although methods and materials similar or equivalent to those
bed herein can be used in the practice or testing of embodiments of the invention,
exemplary methods and/or materials are described below. In case of conflict, the patent
specification, including definitions, will control. In addition, the materials, s, and
examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example
only, with reference to the accompanying drawings. With specific reference now to the
drawings in detail, it is stressed that the particulars shown are by way of example and for
purposes of illustrative sion of embodiments of the invention. In this regard, the
descn’ption taken with the gs makes apparent to those skilled in the art how
embodiments of the ion may be practiced.
In the drawings:
FIGS. lA-B are graphs illustrating durable engraftment of mismatched donor
bone marrow (BM) following lantation of 'mega dose' rigorously T cell depleted
BM and posttranplantation cyclophosphamide. Mice were conditioned with T cell
debulking (TCD), using anti-CD4 and anti—CD8 antibodies, on day -6, and by exposure
to 2.0 Gy total body ation (TBI) on day -1. High dose Cyclophosphamide (CY,
100 mg/kg) was administered on days +3 and +4 post transplant. Donor type chimerism
was evaluated 35 days (Figure 1A) and 95 days (Figure 18) post transplant.
FIGS. 2AeC are dot plot graphs illustrating a typical FACS ism analysis.
Figure 2C depicts that mixed chimerism was achieved in recipients that were
transplanted with ‘mega dose’ (25 x 106) rigorously T cell depleted BM and were
treated with high dose CY. In contrast, recipient mice that received only the
conditioning protocol (Figure 2A) or which were inoculated with only 5 x 106 BM cells
and CY did not exhibit donor type chimerism (Figure 2B).
is a graph illustrating e mixed chimerism 180 and 225 days post
transplant in recipient mice that were transplanted with ‘mega dose’ (25 x 106) T cell
depleted BM and were treated with high dose CY. Of note, mice which were inoculated
with 5 x 106 T cell depleted BM and CY did not exhibit mixed chimerism.
FIGS. 4A—B illustrate the transplantation of donor type or 3rd party skin grafts in
chimeric mice. Figure 4A is a graft illustrating acceptance d by “+”) or rejection
(marked by “—“) of donor type (Balb/c) or 3rd party (C57BL/6) skin grafts in ents
of regular dose (5 x 106) or ‘mega dose’ (25 x 106) T depleted BM, treated with high
dose CY on days +3 and +4 post transplant. Figure 4B is a photograph of donor type
(Balb/c) skin graft (white fur) or 3rd party (C57BL/6) skin graft (black fur) in recipients
of ‘mega dose’ (25 x 106) T depleted BM, treated with high dose CY on days +3 and +4
post transplant.
is a graph illustrating the effect of different doses of irradiation on donor
type ism in recipient mice of ‘mega dose’ (25 x 106) T depleted BM and treated
with high dose CY post transplant.
is a graph illustrating the effect of increased doses of Cyclophosphamide
(CY) on donor type chimerism in recipients of ‘mega dose’ (25 X 106) T depleted BM
and 2 Gy TBI.
is a graph illustrating engraftment of mismatched donor BM achived by
combining ‘mega dose’ CD8+ T cell depleted EM and post trasplant CY. Of note, the
depletion of residual CD8+ T cells from the BM preparation did not have any adverse
impact on the level of chimerism achieved when combing ‘mega dose’ T cell ed
BM cells with post transplant CY.
WO 93920
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The present invention, in some embodiments thereof, relates to a combination
therapy for attaining a stable and long term cell or tissue transplantation.
The ples and operation of the present invention may be better understood
with reference to the drawings and accompanying descriptions.
Before explaining at least one ment of the invention in detail, it is to be
understood that the invention is not necessarily limited in its application to the s
set forth in the following description or exemplified by the Examples. The invention is
e of other embodiments or of being practiced or carried out in s ways.
Also, it is to be understood that the phraseology and terminology employed herein is for
the purpose of description and should not be regarded as limiting.
Application of neic hematopoietic stem cell transplantation (HSCT) has
been limited by the lack of available tched donors within the family or in the
international ries of ted volunteer donors. Conversely, virtually all patients
in need for a transplant have a full-haplotype ched family donor.
The major obstacles to bone marrow transplantation from full-haplotype
mismatched related donors were graft versus host disease (GVHD) and graft rejection.
The use of very large numbers of hematopoietic stem cells with minimal residual T cell
contamination and an aggressive immunosuppressive and myeloablative regimen has
resulted in high rates of engraftment with little severe GVHD. However, immune
reconstitution has been delayed and incomplete after this approach and a significant rate
of transplant related mortality (TRM) is caused by opportunistic infections.
While reducing the t invention to practice, the present inventors have
uncovered that a successful engraftment of mismatched bone marrow can be achieved by
transplantation of rigorously T cell depleted “mega dose’ bone marrow and subsequently
administering to the subject a high-dose cyclophospamide early after transplantation.
The present inventors have shown that such a regimen requires only a short
myeloablative conditioning regimen. The present inventors have further shown
that such a transplantation ure leads to a long and stable chimerism and that
tolerance has been achieved.
As is shown hereinbelow and in the Examples section which follows, the present
inventors have uncovered through laborious experimentation that the combination of
‘mega dose’ T cell depleted bone marrow transplantation (TDBMT) and post transplant
high dose cyclophosphamide (CY) allows for a durable engraftment of mismatched
donor bone marrow (see Figures lA-B and 2A-C). Durable mixed chimerism was
ted for prolonged periods of time after transplantation (180 and 225 days post
transplant in mice, see Figure 3). Importantly, the combination of ‘mega dose’ TDBMT
and high dose CY following transplantation allowed hematopoietic stem cell
engraftment under reduced intensity conditioning (see Figure 5) and ed in tolerance
ion, as indicated by acceptance of donor skin grafts (see Figure 4B).
Thus, according to one aspect of the present invention there is provided a method
of treating a subject in need of a non—syngeneic cell or tissue graft, the method
comprising: (a) transplanting into a subject a dose of T cell ed immature
hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise
less than 5 x 105 CD34r T cells per kilogram body weight of the subject, and wherein the
dose comprises at least about 5 X l06 CD34+ cells per am body weight of the
subject; and subsequently (b) administering to the subject a therapeutically effective
amount of cyclophosphamide, wherein the therapeutically effective amount comprises
—200 mg per kilogram body weight, thereby treating the subject.
As used herein, the term ing” includes abrogating, substantially ting,
slowing or reversing the progression of a condition, substantially ameliorating clinical or
aesthetical symptoms of a condition or substantially preventing the appearance of
clinical or aesthetical symptoms of a condition.
As used , the term "subject" or “subject in need thereof” refers to a
mammal, preferably a human being, male or female at any age that is in need. of a cell or
tissue transplantation. Typically the subject is in need of cell or tissue transplantation
(also referred to herein as recipient) due to a disorder or a pathological or undesired
condition, state, or syndrome, or a al, morphological or physiological abnormality
which is amenable to treatment via cell or tissue transplantation.
According to an embodiment the subject is in need of tissue regeneration (solid
or soft ) such as due to aging, trauma, wound or any ogical condition which
results in loss of organ functionality.
According to one embodiment the subject has a malignant disease.
According to one ment the ant disease is a hematopoietic cancer.
2012/050542
Exemplary hematopoietic cancers include, but are not limited to, acute
lymphoblastic leukemia (ALL), T-cell acute lymphocytic leukemia (T-ALL), acute
myelocytic leukemia (AML), acute nonlymphoblastic leukemia , chronic
cytic leukemia (CLL), chronic myelocytic leukemia (CML), T—cell
prolymphocytic leukemia, B—cell prolymphocytic ia, Juvenile myelomonocytic
leukemia, n's Lymphoma, non- Hodgkin's Lymphoma, Extranodal natural
killei'flT-cell lymphoma, Cutaneous T—cell lymphoma, Enteropathy type T-cell
lymphoma, Angioimmunoblastic T—cell lymphoma, Anaplastic large T/null~cell
lymphoma, Subcutaneous ulitis—like T-cell lymphoma, Unspecified T—cell
lymphoma, Diffuse large B—cell lymphoma (DLBCL), B—cell chronic lymphocytic
leukemia (B-CLL)/chr0nic id leukemia (CLL), Chronic lymphocytic
leukemia/small lymphocytic lymphoma, Extranodal marginal zone B-cell lymphomas -
mucosa—associated id tissue lymphomas, Follicular lymphoma, Mantle cell
lymphoma, Nodal marginal zone B-cell lymphoma, Burkitt lymphoma, Hairy cell
leukemia, Primary central s system lymphoma, c marginal zone B-cell
lymphoma, Lymphoplasmocytic lymphoma, Primary mediastinal B—cell lymphoma,
precursor T-cell leukemia/lymphoma, MALT lymphoma, Mycosis fungoides and
multiple myeloma.
According to one embodiment the hematopoietic cancer comprises a leukemia or
a lymphoma.
According to one embodiment the subject has a non—malignant disease.
According to one embodiment the non-malignant disease is a genetic disease or
disorder, an autoimmune e or a metabolic disorder.
Exemplary non—malignant diseases e, but are not limited to, severe
combined immunodeficiency syndromes (SCID), sickle cell disease (sickle cell anemia),
congenital neutropenia, thrombocytopenia, aplastic anemia (e. g. severe aplastic anemia),
myelodysplastic syndrome, monosomy 7, osteopetrosis, Gaucher's disease, Hurler's
disease, metachromatic leukodystrophy, adrenal ystrophy, thalassemia, congenital
or genetically—deteimined hematopoietic ality, adenosine deaminase (ADA),
lupus, autoimmune hepatitis, celiac disease, type I diabetes us, Grave’s disease,
Guillain-Barr syndrome, Myasthenia gravis, Rheumatoid arthritis, derma and
psoriasis.
According to one embodiment the subject of the present invention may suffer
from any of a cardiovascular disease, a rheumatoid disease, a glandular disease, a
intestinal disease, a cutaneous disease, a hepatic disease, a neurological disease, a
muscular disease, a nephric e, a connective tissue disease, a systemic disease
and/or a disease related to reproduction, treatable by cell or tissue transplantation.
As used herein, the phrase “cell or tissue graft” refers to a bodily cell (eg. a
single cell or a group of cells) or tissue (eg. solid tissues or soft tissues, which may be
transplanted in full or in part). Exemplary tissues which may be transplanted according
to the present teachings include, but are not d to, liver, pancreas, spleen, kidney,
heart, lung, skin, ine and lymphoid/hematopoietic tissues (e. g. lymph node, Peyer’s
s, thymus or bone marrow). Exemplary cells which may be lanted
according to the present teachings include, but are not limited to, immature
hematopoietic cells ing stem cells. The present invention also contemplates
transplantation of whole organs, such as for example, , heart, lung, liver, pancreas
or spleen.
According to one embodiment, the cell or tissue graft comprises immature
poietic cells.
According to one embodiment, the method is effected using a cell or ,
which is non—syngeneic with the subject.
Depending on the ation, the method may be effected using a cell or tissue
graft which is allogeneic or xenogeneic with the subject.
As used herein, the term “allogeneic” refers to a cell or tissue which is derived
from a donor who is of the same s as the subject, but which is substantially non—
clonal with the subject. Typically, outbred, non~zygotic twin mammals of the same
species are allogeneic with each other. It will be appreciated that an allogeneic donor
may be HLA cal or HLA non~identical (i.e. displaying one or more disparate
HLA determinants) with respect to the subject.
According to one embodiment, the allogeneic donor is an HLA matched sibling,
an HLA matched unrelated donor, an HLA haploidentical related donor or a donor
displaying one or more disparate HLA determinants.
As used herein, the term “xenogeneic” refers to a cell or tissue which
substantially expresses antigens of a different species relative to the species of a
substantial proportion of the lymphocytes of the subject. Typically, outbred mammals
of different species are xenogeneic with each other.
The present ion envisages that xenogeneic cells or tissues are derived from
a variety of species such as, but not limited to, bovines (e. g., cow), equines (e.g, horse),
porcines (e. g. pig), ovids (e.g., goat, sheep), felines (e.g., Felis ica), s (e.g.,
Canis domestica), rodents (e. g., mouse, rat, , guinea pig, gerbil, hamster) or
primates (e.g., chimpanzee, rhesus monkey, e monkey, marmoset).
Cells or tissues of xenogeneic origin (e.g. porcine origin) are preferably obtained
from a source which is known to be free of zoonoses, such as porcine endogenous
retroviruses. Similarly, human—derived cells or tissues are preferably obtained from
substantially pathogen~free sources.
According to an embodiment of the present invention, both the subject and the
donor are humans.
Depending on the application and available sources, the cell or tissue graft of the
present invention may be obtained from a prenatal organism, postnatal organism, an
adult or a r donor. Moreover, depending on the application needed, the cell or
tissue graft may be naive or genetically modified. Determination of the type of cell or
tissue graft to be used is well within the ability of one of ordinary skill in the art.
Furthermore, any method known in the art may be employed to obtain a cell or tissue
graft (e. g. for transplantation).
As mentioned, a dose of T cell depleted hematopoietic cell or tissue comprising
re hematopoietic cells (including e.g. CD345, are transplanted into a subject.
According to one embodiment, the T cell depleted re hematopoietic cells
are non—syngeneic (e. g. allogeneic or xenogeneic) with the t.
ing to one embodiment, the T cell depleted immature hematopoietic cells
and the cell or tissue graft are syngeneic (e. g. obtained from the same donor).
As used herein the phrase “immature hematopoietic cells” refers to a
poietic tissue or cell preparation comprising precursor hematopoietic cells. Such
tissue/cell preparation includes or is derived from a biological sample, for e, bone
marrow, mobilized peripheral blood (e. g. zation of CD34 cells to enhance their
concentration), cord blood (eg. umbilical cord), fetal liver, yolk sac and/or placenta.
Additionally, purified CD34+ cells or other hematopoietic stem cells such as CDl3l+
cells can be used in accordance with the present teachings, either with or without ex-vivo
ion.
ing to one embodiment, the immature poietic cells complise T cell
depleted immature hematopoietic cells.
As used herein the phrase “T cell depleted immature hematopoietic cells” refers
to a population of hematopoietic cells which are depleted of T lymphocytes. The T cell
depleted immature hematopoietic cells, may include e.g. CD34+, CD33+ and/or CD56+
cells. The T cell depleted re hematopoietic cells may be depleted of CD3+ cells,
CD2+ cells, CD8+ cells, CD4+ cells, (ll/[3 T cells and/or 7/5 T cells.
According to one embodiment, the immature hematopoietic cells complise T cell
depleted G—CSF mobilized blood cells enriched for CD34+ immature poietic
cells.
According to one embodiment, the immature hematopoietic cells are depleted of
CD3+ T cells.
According to an embodiment, the T cell depleted immature hematopoietic cells
comprise less than 50 x lo5 CD3+ T cells, 40 x 105 CD3+ T cells, 30 x 105 CD3+ T cells,
x lo5 CD3+ T cells, 15 x lo5 CD3+ T cells, 10 x lo5 CD3+ T cells, 9 x lo5 CD3+ T
cells, 8 x 105 CD3+ T cells, 7 x 105 CD3+ T cells, 6 x lo5 CD3+ T cells, 5 x 105 c133+ T
cells, 4 x 105 CD3+ T cells, 3 x lo5 CD3+ T cells, 2 x lo5 cm+ T cells or 1 x lo5 cos+
T cells per kilogram body weight of the subject.
According to a specific embodiment, the T cell depleted immature hematopoietic
cells comprise less than 5 X 105 CD3+ T cells per kilogram body weight of the subject.
According to a specific embodiment the T cell depleted immature hematopoietic
cells comprise less than 20 x 105 CD3+ T cells but more than 10 CD3+ T cells.
ing to an embodiment, the T cell depleted immature poietic cells
comprise at least 1 x 103 — l x 105 CD3+ Tcells.
According to one embodiment, the immature hematopoietic cells are depleted of
CD8+ cells.
According to an embodiment, the T cell ed immature hematopoietic cells
comprise less than 1 x 104— 4 x 105 CD8+ cells per kilogram body weight of the subject.
According to an embodiment, the T cell depleted immature hematopoietic cells
comprise less than 50 x 105 (:le+ cells, 25 x lo5 cps+ cells, 15 x 105 CD8+ cells, 10 x
lo5 CD8+ cells, 9 x lo5 cps+ cells, 8 x lo5 CD8+ cells, 7 x 105 CD8+ cells, 6 x lo5 CD8+
cells, 5 x 105 CD8+ cells, 4 x 105 CD8+ cells, 3 x 105 CD8" cells, 2 x lo5 cps+ cells, 1 x
lo5 CD8+ cells, 9 x lo" CD8+ cells, 8 x 10“ CD8+ cells, 7 x lo4 CD8+ cells, 6 x lo4 CD8+
cells, 5 x 10“ CD8+ cells, 4 x 10“ CD8+ cells, 3 x lo4 CD8+ cells, 2 x 10“ CD8+ cells or 1
x 104 CD8+ cells per kilogram body weight of the subject.
According to a specific ment, the T cell depleted immature hematopoietic
cells comprise less than 4 x 105 CD8+ cells per kilogram body weight of the subject.
According to a specific embodiment the T cell depleted immature hematopoietic
cells comprise less than 4 x 105 CD8+ cells but more than 10 CD8+ cells.
According to an embodiment, the T cell depleted immature hematopoietic cells
comprise less than 1 X 106 CD8+ TCRa/B- cells per am body weight of the t.
According to an ment, the T cell depleted immature hematopoietic cells
comprise less than l x lo6 CD8+ TCRa/B’ cells, 0.5 x lo6 CD8+ TCRa/B‘ cells, 1 x lo5
CD8+ TCRa/B‘ cells, 0.5 x 105 CD8+ TCRd/B' cells, 1 x 104 CD8+ TCRo/B' cells, 0.5 x
lo4 CD8+ 'l‘CRcl/B~ cells, 1 x lo3 CD8+ TCRa/B‘ cells or 0.5 x 103 CD8+ TCRo/B' cells
per kilogram body weight of the t.
According to a specific embodiment, the T cell depleted immature hematopoietic
cells comprise less than 1 x 106 CD84r TCROl/B~ cells per kilogram body weight of the
subject.
According to a specific embodiment the T cell depleted immature hematopoietic
cells comprise less than 1 x 106 CD8+ TCRa/B' cells but more than 10 CD8+ TCRO/B’
cells.
According to one embodiment, the immature poietic cells are depleted of
B cells.
According to an ment, the immature hematopoietic cells are depleted of B
cells (CD19+ and/or CD20+ B cells).
According to an embodiment, the re hematopoietic cells comprise less
than 50 x 105 B cells, 40 x 105 B cells, 30 x 105 B cells, 20 x 105 B cells, 10 x 105 B
cells, 9 x lo5 B cells, 8 x lo5 B cells, 7 x 105 B cells, 6 x lo5 B cells, 5 x lo5 B cells, 4 x
105 B cells, 3 X 105 B cells, 2 x 105 B cells or 1 x 105 B cells per kilogram body weight
of the subject.
WO 93920
According to a specific embodiment, the re hematopoietic cells comprise
less than 4 x 105 B cells per kilogram body weight of the subject. According to a
specific embodiment the immature hematopoietic cells comprise less than 50 x 105 B
cells but more than 10 B cells.
Depletion of T cells, e.g. CD3+, CD2+, TCRU/B+, CD4+ and/or CD8+ cells, or
B cells, e. g. CDl9+ and/or CD20+ cells, may be carried out using any method known in
the art, such as by eradication (e. g. killing) with specific antibodies or by affinity based
purification e.g. such as by the use of magnetic cell separation techniques, FACS sorter
and/01' capture ELISA labeling.
Such methods are described herein and in THE HANDBOOK OF
EXPERIMENTAL IMMUNOLOGY, Volumes 1 to 4, (D.N. Weir, editor) and FLOW
CYTOMETRY AND CELL SORTING (A. Radbruch, editor, Springer Verlag, 1992).
For e, cells can be sorted by, for example, flow cytometry or FACS. Thus,
fluorescence activated cell sorting (FACS) may be used and may have varying degrees
of color channels, low angle and obtuse light scattering detecting channels, and
impedance channels. Any ligand-dependent separation techniques known in the art may
be used in ction with both positive and negative separation techniques that rely on
the al properties of the cells rather than antibody affinity, including but not limited
to ation and y nt centrifugation.
Other s for cell sorting include, for e, panning and separation
using affinity techniques, including those ques using solid supports such as plates,
beads and columns. Thus, biological samples may be ted by "panning" with an
antibody attached to a solid matrix, e.g. to a plate.
Alternatively, cells may be sorted/separated by magnetic separation techniques,
and some of these methods utilize magnetic beads. Different magnetic beads are
available from a number of sources, including for example, Dynal (Norway), Advanced
Magnetics (Cambridge, MA, USA), lmmuncon (Philadelphia, U.S.A.), lmmunotec
(Marseille, France), Invitrogen, Stem cell Technologies (USA) and Cellpro (USA).
Alternatively, dies can be biotinylated or conjugated with digoxigenin and used in
conjunction with avidin or anti-digoxigenin coated affinity columns.
ing to an embodiment, different depletion/separation methods can be
combined, for example, magnetic cell sorting can be combined with FACS, to increase
the separation quality or to allow sorting by multiple ters.
According to one embodiment, the T cell depleted immature hematopoietic cells
are obtained by T cell ing (TCD).
T cell debulking may be effected using antibodies, including e.g. anti—CD8
antibodies, anti-CD4 antibodies, anti—CD3 antibodies, anti—CD2 antibodies, anti—TCRtx/B
antibodies and/or anti—TCRy/B antibodies.
According to one ment, depletion of B cells is effected by B cell
IO debulking.
B cell debulking may be effected using antibodies, including e.g. anti-CD19 or
D20 antibodies. Alternatively, debulking iii—viva of B cells can be attained by
infusion of anti—CD20 antibodies.
Alternatively, positive ion of CD34+ or CD13l+ stem cells may be cairied
out using e. g. magnetic cell separation techniques, FACS sorter and/or e ELISA
labeling as described in r detail above.
As mentioned, T cell or B cell debulking may be effected in-vitro or in-vivo (eg.
in a donor prior to acquiring re hematopoietic cells therefrom).
According to one ment, the T cell depleted immature hematopoietic cells
(e. g. comprising CD34+ cells) comprise T cell depleted bone marrow cells, T cell
depleted mobilized peiipheral blood progenitor cells (e. g. mobilized by G—CSF), T cell
depleted cord blood/fetal liver/yolk sac and/or, pun'fied CD34+ cells (harvested from all
the sources mentioned above e.g. from bone marrow and/or from G-CSF mobilized
peripheral blood itor cells) and ed by positive selection (e.g. with magnetic
beads using an anti—CD34 antibody). In addition purified CD34+ cells expanded ex—vivo
to increase cell numbers are also contemplated by the present methods.
According to an embodiment of the present invention, the subject is administered
with a dose of T cell depleted immature hematopoietic cells comprising at least about, 4
x 106, 4.5 x 106, 5 x 106, 5.5 x 106, 6 x 106, 6.5 x 106, 7 x 106, 7.5 x 106, s x 106, 8.5 x
106, 9 x 106, 9.5 x 106., 10 x 106, 12.5 x106, 15 x 106, 20 x 106, 25 x 106, 30 x 106, 35 x
106, 40 x 106, 45 x 106, 50 x 106, 60 x 106, 70 x 106’ 80 x 106, 90 x 106 CD34+ cells per
am body weight.
According to a specific embodiment, the subject is administered a dose of T cell
ed immature hematopoietic cells comprising at least about 10 x 106 CD34+ cells
per kilogram body .
According to a specific ment, the subject is administered a dose of T cell
depleted immature hematopoietic cells comprising at least about 5 X 106 CD34+ cells
per kilogram body weight.
According to one embodiment, the subject is administered a dose of T cell
depleted immature poietic cells comprising a range of about 4—30 X 106, 4—40 x
106, 4-50 x 106,460 x 106, 4-70 x 106, 4-80 x 106, 4-90 x 10": 4-100 x 106, 5-10 x 106, 5-
20 x 106, 5-30 x 1.06, 5-40 x 106, 5-50 x 106, 5-60 x 106, 5-70 x 106, 5-80 x 106, 5-90 x
106, 5-100 x 106, 10-20 x 106, 10-30 x 106,10-40 x 106, 10-50 x 106,10—60 x 106,10-70 x
106, 10-80 x 10", 10-90 x 106, 10-100 x 106, 20-30 x 106, 20-40 x 106, 20-50 x 106, 20-60
x 106, 20-70 x 106, 20—80 x 106, 20-90 x 106, 20-100 x 106, 30-40 x 106, 30-50 x 106, 30-
60 x 106, 30-70 x 106, 30-80 x 106, 30-90 x 106, 30-100 x 106, 40-50 x 106, 40-60 x 106,
40-70 x 106, 40-80 x 106, 40-90 x 106, 40100 x 106, 50-60 x 106, 50-70 x 106, 50-80 x
106, 50-90 x 106, 50100 x 106, 60-70 x 106, 60-80 x 106, 60-90 x 106, 60-100 x 106.
70-80 x 106, 70-90 x 106, 70-100 x 106, 80—90 x 106, 80-100 x 106 CD34+ cells per
kilogram body weight of the subject.
According to a c embodiment, the subject is administered a dose of T cell
depleted immature hematopoietic cells sing a range of about 5—40 x 106 CD34+
cells per kilogram body weight.
The T cell depleted immature hematopoietic cells of the present invention
be transplanted into a recipient using any method known in the art for cell
transplantation, such as but not limited to, cell infusion (e.g. I.V.), via an intraperitoneal
route or via an intrabone route.
As mentioned, the subject of the instant invention may r be transplanted
with a cell or tissue graft (e. g. liver, pancreas, spleen, kidney, heart, lung, skin, intestine
and/or lymphoid/hematopoietic tissues).
Transplanting the cell or tissue into the subject may be effected in numerous
ways, depending on various parameters, such as, for example, the cell or tissue type; the
type, stage or severity of the ent's disease (cg. organ failure); the physical or
logical parameters specific to the subject; and/or the desired therapeutic outcome.
Transplanting a cell or tissue graft of the present invention may be effected by
transplanting the cell or tissue graft into any one of various anatomical locations,
depending on the ation. The cell or tissue graft may be transplanted into a
homotopic anatomical location (a normal anatomical location for the lant), or into
U] an ectopic ical on (an abnormal anatomical location for the transplant).
Depending on the application, the cell or tissue graft may be advantageously implanted
under the renal capsule, or into the kidney, the ular fat, the sub cutis, the omentum,
the portal vein, the liver, the spleen, the heart cavity, the heart, the chest cavity, the lung,
the skin, the pancreas and/or the intra abdominal space.
For example, a liver tissue according to the t teachings may be
transplanted into the liver, the portal vein, the renal capsule, the sub—cutis, the omentum,
the spleen, and the abdominal space. Transplantation of a liver into various
anatomical locations such as these is commonly practiced in the art to treat diseases
amenable to treatment via c transplantation (eg. hepatic failure). Similarly,
transplanting a pancreatic tissue according to the present invention may be
advantageously ed by transplanting the tissue into the portal vein, the liver, the
pancreas, the testicular fat, the sub-cutis, the omentum, an intestinal loop (the subserosa
of a U loop of the small intestine) and/or the intra-abdominal space. Transplantation of
pancreatic tissue may be used to treat diseases amenable to treatment via pancreatic
transplantation (eg. diabetes). Likewise, transplantation of tissues such as a kidney, a
heart, a lung or skin tissue may be d out into any anatomical location described
above for the purpose of treating recipients suffering from, for example, renal e,
heart failure, lung failure or skin damage (e.g., burns).
Optionally, when transplanting a cell or tissue graft of the present invention into
a subject having a defective organ, it may be advantageous to first at least partially
remove the failed organ from the subject so as to enable optimal development of the
transplant, and ural/functional integration thereof with the anatomy/physiology of
the subject.
The method of the present invention also envisions co-transplantation of several
organs (e.g. heart and lung, liver and spleen, pancreas and bone marrow e.g.
poietic stem cells, kidney and bone marrow e.g. hematopoietic stem cells, etc.)
in case the subject may be beneficially affected by such a procedure.
ing to one embodiment, the co-transplantation comprises transplantation
of re hematopoietic cells and a solid tissue/organ or a number of solid
organs/tissues.
ing to one ment, the immature hematopoietic cells and the solid
Ul organ are obtained from the same donor.
According to one embodiment, the cell or tissue graft (e.g. solid organ) is
transplanted into the subject prior to, concomitantly with or following transplanting of
the T cell depleted immature hematopoietic cells (e.g. sing CD34+ cells) into the
subject.
Following transplantation of the cell or tissue graft into the subject, it is
advisable, according to standard medical practice, to monitor the growth functionality
and immuno—compatability of the organ according to any one of various standard art
techniques. For example, the functionality of a atic tissue transplant may be
monitored following transplantation by standard pancreas function tests (eg. analysis of
serum levels of insulin). se, a liver tissue transplant may be monitored following
lantation by standard liver function tests (e.g. analysis of serum levels of albumin,
total protein, ALT, AST, and bilirubin, and is of blood-clotting time). Structural
development of the cell or tissue graft may be monitored via computerized tomography,
or ultrasound imaging.
Regardless of the transplant type, in order to reduce, by at least about 30 %, 4O
%, 50 %, 6O %, 7O %, 80 %, 9O % or 95 %, or preferably avoid graft rejection and/or
graft versus host disease (GVHD), the present invention plates post transplant
administration of cyclophosphamide.
According to one embodiment, the t invention further contemplates
administration of cyclophosphamide prior to transplantation (e.g. on days 4, 3 or 2 prior
to transplantation, i.e. "D4, —3 or O.) in addition to the administration following
transplantation as described herein.
Of note, the date of transplantation (of the cell or tissue graft) is considered
Tzzero.
As used herein, the term ”cyclophosphamide" refers to the nitrogen mustard
alkylating agent which specifically adds an alkyl group (CnH2n+1) to DNA (also known
as cytophosphane). In a specific embodiment, the cyclophosphamide refers to the
2012/050542
lar a C7H15CBNZOZP'HZO and the chemical name 2-[bis(2—
chloroethyl)amino]tetrahydro—ZH-1,3,2-oxazaphosphorine '2-oxide monohydrate.
Cyclophosphamide is commercially available from e.g. Zydus (German Remedies),
Roxane Laboratories ehringer eim, Bristol~Myers Squibb Co — Mead
Johnson and Co, and Pfizer — Pharmacia & Upjohn, under the brand names of n,
Cytoxan, Neosar, Procytox and une.
A therapeutically effective amount of cyclophosphamide is typically
administered to the subject following transplantation of the cell or tissue graft.
Without being bound to theory, a therapeutically effective amount is an amount
of cyclophosphamide efficient for killing ted donor or host alloreactive T cells
without being toxic to the subject.
For example, in case of cell or tissue graft, the therapeutic effective amount of
cyclophosphamide comprises about 1—25 mg, 1—50 mg, 1—75 mg, 1—100 mg, 1—250 mg,
1—500 mg, l—750 mg, 1—1000 mg, 5-50 mg, 575 mg, 5400 mg, 5—250 mg, 5-500 mg, 5—
750 mg, 5—1000 mg, 10-50 mg, 10-75 mg, 10—100 mg, 10—250 mg, 10-500
mg, 10-750
mg, 10-1000 mg, 25—50 mg, 25-75 mg, 25-100 mg, 25—125 mg, 25—200 mg, 25-300 mg,
-400 mg, 25-500 mg, 25-750 mg, 25-1000 mg, 50-75 mg, 50-100 mg, 50—125
mg, 50—
150 mg, 50—175 mg, 50—200 mg, 50—250 mg, 50-500 mg, 50—1000 mg, 75-100
mg, 75-
125 mg, 75~150 mg, 75~250 mg, 75—500 mg, 75—1000 mg, 100—125 mg, 100-150 mg,
100-200 mg, 100—300 mg, 100—400 mg, 100—500 mg, 100—1000 mg, 125—150 mg, 125-
250 mg, 125-500 mg, 125—1000 mg, 150—200 mg, 150—300 mg, 150-500 mg, 150-1000
mg, 200-300 mg, 200-400 mg, 200600 mg, 200—750 mg, 200—1000 mg, 250-500 mg,
250-750 mg, 250—1000 mg per kilogram body weight of the subject.
According to a specific embodiment, the therapeutic effective amount of
cyclophosphamide is about 25200 mg per kilogram body weight of the subject.
As illustrated in the Examples section which follows, the present inventors have
shown that administration of two doses of cyclophosphamide post transplant (on days 3
and 4 post transplant) allows for a e engraftment and tolerance of ‘mega dose’ T
cell depleted mismatched donor bone marrow.
According to one embodiment, cyclophosphamide is administered in a single
dose.
According to one embodiment, hosphamide is administered in multiple
doses, e.g. in 2, 3, 4, 5 doses or more.
According to a specific embodiment, cyclophosphamide is administered in two
doses.
According to one embodiment, cyclophosphamide is administered daily such as
once a day or twice a day.
The dose of each cyclophosphamide administration may comprise about 5 mg,
7.5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg,
110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg,
210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg,
350 mg, 400 mg, 450 mg or 500 mg per kilogram body weight of the subject.
According to a specific embodiment, the dose ophosphamide is 50 mg per
kilogram body weight of the subject.
As mentioned, cyclophosphamide is administered post transplantation. Thus, for
example, cyclophosphamide may be administered to the t 1, 2, 3, 4, 5, 6, 7, 8, 9,
days or more post transplant (i.e., T+1, +2, +3, +4, +5, +6, +7, +8, +9, +10).
According to a c embodiment, cyclophosphamide is administered to the subject
in two doses 3 and 4 days post transplant.
According to an embodiment, cyclophosphamide is administered prior to
transplantation and post lantation. Thus, for e, cyclophosphamide may be
administered to the subject 3 days prior to transplantation (T-3) and then post
transplantation (e. g. on days T+3, +4, etc.).
The number of administrations and the therapeutically effective amount of
cyclophosphamide may be adjusted as needed taking into account the type of
k)U: transplantation and the subject's response to the regimen. Determination of the number
of administrations and the therapeutically effective amount is well within the capability
of those skilled in the art, especially in light of the detailed disclosure provided herein.
In order to facilitate engraftment of the cell or tissue graft, the method may
further advantageously comprise ioning the subject with an additional
immunosuppressive drug and/or immunosuppressive irradiation prior to, concomitantly
with or following transplantation of the cell or tissue graft.
It will be appreciated that in situations in which the cell or tissue graft (e. g. solid
organ) is transplanted prior to the T cell depleted immature hematopoietic cells, it is
advisable to use general immune suppressive agents (eg. cyclosporine A, as described
in further detail below) in order to avoid organ rejection. Once the T cell depleted
immature hematopoietic cells are transplanted and chimerisrn is ed, the general
immune suppression agents may be tapered down and subsequently stopped. In contrast
in situations in which the cell or tissue graft (e. g. solid organ) is lanted uent
to the T cell depleted immature hematopoietic cells, after chimerism induction, the use
of general immune suppression may not required.
Ample guidance for selecting and administering suitable immunosuppressive
ns for transplantation is ed in the ture of the art (for example, refer to:
Kirkpatrick CH. and Rowlands DT Jr., 1992. JAMA. 268, 2952; Higgins RM. et al.,
1996. Lancet 348, 1208; Suthanthiran M. and Strom TB., 1996. New Engl. J. Med. 331,
365; Midthun DE. et al., 1997. Mayo Clin Proc. 72, 175; Morrison VA. et al., 1994. Am
J Med. 97, 14; Hanto DW., 1995. Annu Rev Med. 46, 381; Senderowicz AM. et al.,
1997. Ann Intern Med. 126, 882; Vincenti F. et a1., 1998. New Engl. J. Med. 338, 161;
Dantal J. et a1. 1998. Lancet 351, 623).
Thus, according to an embodiment of the present invention, the subject is
conditioned under reduced intensity conditioning prior to transplantation of a cell or
tissue graft,
According to an embodiment, the reduced intensity ioning is effected for
up to 2 weeks (e.g. 1—10 or l~7 days) prior to transplantation of the cell or tissue graft.
Thus, for example, the subject may be treated with a myeloablative or non-
myeloablative conditioning. Such conditioning may comprise, for example and as
described in detail in the Examples section which s, in-vivo T cell debulking e.g.
by D4 dy, anti-CD8 antibody, anti—CD3 (OKT3) antibodies, anti—CD52
antibodies (e.g. CAMPATH) and/or anti—thymocyte globulin (ATG) antibody (e.g. 6
days prior to transplantation at a therapeutic effective dose of about 300 n g each).
The conditioning may additionally or alternatively comprise total body
ation (TBI), total lymphoid irradiation (TLI, i.e. exposure of all lymph nodes, the
thymus, and spleen), a chemotherapeutic agent and/or an antibody immunotherapy.
WO 93920
Thus, according to one embodiment, the TBI comprises a single or fractionated
ation dose within the range of 0.5-1 Gy, 0.5-1.5 Gy, 0.5-2.5 Gy, 0.5—5 Gy, 0.5-7.5
Gy, 0.5—10 Gy, 0.5-15 Gy, 1—1.5 Gy, 1-2 Gy, 1-2.5 Gy, 1—3 Gy, l-3.5 Gy, 1-4 Gy, 1—4.5
Gy, 1—1.5 Gy, 1—7.5 Gy, l-lO Gy, 2—3 Gy, 2—4 Gy, 2-5 Gy, 2—6 Gy, 2-7 Gy, 2—8 Gy, 2—9
Ur Gy, 2-10 Gy, 3—4 Gy, 3—5 Gy, 3—6 Gy, 3—7 Gy, 3—8 Gy, 3—9 Gy, 3-10 Gy, 4—5 Gy, 4-6 Gy,
4—7 Gy, 4—8 Gy, 4-9 Gy, 4—10 Gy, 5—6 Gy, 5—7 Gy, 5—8 Gy, 5—9 Gy, 5—10 Gy, 6—7 Gy, 6—8
Gy, 6—9 Gy, 6—10 Gy, 7—8 Gy, 7-9 Gy, 7-10 Gy, 8—9 Gy, 8—10 Gy, 10—12 Gy or 10—15 Gy.
According to a specific ment, the TBI comprises a single or fractionated
irradiation dose within the range of 1—3.5 Gy.
According to an embodiment, TBl treatment is administered to the subject 1—10
days (e.g. 1—3 days) prior to transplantation. According to one embodiment, the subject
is conditioned once with TBI l or 2 days prior to transplantation.
According to a specific embodiment, the TLI comprises an irradiation dose
within the range of 0.5-1 Gy, 0.5—1.5 Gy, 0.5—2.5 Gy, 0.5—5 Gy, 0.5-7.5 Gy, 0.5—10 Gy,
0.5-15 Gy, 1—1.5 Gy, 1-2 Gy, 1—2.5 Gy, 1-3 Gy, 1—3.5 Gy, 1-4 Gy, 1-4.5 Gy, 1—1.5 Gy, l-
7.5 Gy, l-lO Gy, 2-3 Gy, 2—4 Gy, 2-5 Gy, 2-6 Gy, 2-7 Gy, 2—8 Gy, 2-9 Gy, 2-10 Gy, 3-4
Gy, 3—5 Gy, 3-6 Gy, 3-7 Gy, 3—8 Gy, 3-9 Gy, 3-10 Gy, 4-5 Gy, 4—6 Gy, 4-7 Gy, 4-8 Gy,
4—9 Gy, 4—10 Gy, 5—6 Gy, 5—7 Gy, 5-8 Gy, 5—9 Gy, 5-10 Gy, 6—7 Gy, 6—8 Gy, 6—9 Gy, 6—
Gy, 7—8 Gy. 7—9 Gy, 7—10 Gy, 8-9 Gy, 8—10 Gy, 10—12 Gy, 10—15 Gy, 10—20 Gy, 10—
30 Gy, 10—40 Gy, 10—50 Gy, 0.5—20 Gy, 0.5—30 Gy, 0.5—40 Gy or 05—50 Gy.
ing to a specific embodiment, the TLI ses a single or fractionated
irradiation dose within the range of 1—3.5 Gy.
ing to an embodiment, TLI treatment is administered to the subject 1—10
days (e. g. 1—3 days) prior to transplantation. According to one embodiment, the subject
is conditioned once with TL12—7 days prior to transplantation.
According to one embodiment, the conditioning comprises a chemotherapeutic
agent. Exemplary chemotherapeutic agents include, but are not limited to, Busulfan,
Myleran, Busulfex, Fludarabine, Melphalan and Thiotepa and cyclophosphamide. The
chemotherapeutic agent/s may be administered to the subject in a single dose or in
several doses 6g. 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses (cg. daily doses) prior to
transplantation. ing to one embodiment, the subject is administered a
WO 93920
chemotherapeutic agent (e. g. Fludarabine e.g. at a dose of about 30 mg/mZ/day) for 5
consecutive days prior to transplantation (e. g. on days -7 to -3).
According to one embodiment, the ioning comprises an antibody
immunotherapy. Exemplary antibodies include, but are not limited to, an anti—CD52
antibody (e.g. Alemtuzumab sold under the brand names of e.g. h, MabCampath,
Campath—lH and Lemtrada) and an anti-thymocyte globulin (ATG) agent [c.g.
Thymoglobulin (rabbit ATG, rATG, available from Genzyme) and Atgam (equine ATG,
eATG, available from Pfizer)]. Additional antibody immunotherapy may se anti—
CD3 (OKT3), anti~CD4 or anti-CD8 . According to one embodiment, the antibody
is administered to the subject in a single dose or in several doses e.g. 2, 3, 4, 5, 6, 7, 8, 9,
or more doses (eg. daily doses) prior to transplantation (e.g. 6 days prior to
transplantation).
According to one embodiment, the subject is not treated chronically (e.g. for a
prolonged period of time, e.g. for more than 10 days) with GVHD prophylaxis post
transplant.
According to one embodiment, in case of relapse after hematopoietic stem cell
transplantation, the subject may be further treated by donor lymphocyte infusions
(DLIs). For example, the t may be administered with graded doses of T-cells as
previously described by Dazzi et al [Dazzi, Szydlo et al., Blood, (2000) 96: 2712—6]
fully incorporated herein by reference.
According to one embodiment, the subject may be treated by on of about
0.5 - 5 x 104 CD3+ lymphocytes per kg recipient body weight (eg. 1 x 104 CD3+
lymphocytes, e.g. unmanipulated CD3+ lymphocytes, per kg recipient body weight) for
the treatment of relapse following T cell depleted haploidentical transplantation.
According to one embodiment, a patient with early molecular and/or
hematological relapse will further be treated with a first dose of about 1 x 104 CD3+
cells per Kg recipient body . In the absence of GVHD, the second on of
about 1 x 105 CD3+ cells per kg recipient body weight will lly be given about 45
days later followed 2 months later by a third dose of about 1 x 106 CD3“ cells per kg
recipient body weight. It will be appreciated that donors typically undergo a
leukoapheresis to collect cytes prior to mobilization of hematopoietic cells (e. g.
for transplantation). The frozen products are thawed as needed and infused quickly over
WO 93920
a period of 5—10 minutes. ts ting acute GVHD or who fail to trate
hematological engraftment lly will not receive any DLI.
According to one embodiment, a patient with relapsing B cell non-Hodgkin
lymphoma will lly be further treated with rituximab (e.g. 375 mg/m2 weekly for
about 4 weeks) with DLI concomitant with the second rituximab dose.
According to one embodiment, a patient with relapsing multiple myeloma will
be further treated with bortezomib (e.g. 1.3 mg/sqm on days 1, 4, 8 and ll) before
starting DLI.
ing to one embodiment, no post—DLl immunosuppressive agents will be
used along with the present methods.
According to an aspect of the present invention, there is provided a method of
treating a subject in need of a T cell depleted immature hematopoietic cell
transplantation, the method comprising: (a) transplanting into a conditioned subject a
dose of T cell depleted immature poietic cells, wherein the T cell depleted
re hematopoietic cells comprise less than 5 X 105 CD3+ cells per kilogram body
weight of the subject, and n the dose comprises at least about 5 x 106 CD34+
cells per kilogram body weight of the subject; and subsequently (b) administering to the
subject a therapeutically effective amount of cyclophosphamide, wherein the
therapeutically effective amount comprises 25—200 mg per kilogram body weight,
thereby treating the subject.
According to an aspect of the present invention, there is provided a method of
treating a subject in need of an immature hematopoietic cell transplantation, the method
comprising: (a) conditioning a subject under a reduced intensity conditioning ol,
wherein the reduced intensity conditioning comprises a total body irradiation (TBI) and
a chemotherapeutic agent; (b) transplanting into the t a dose of T cell depleted
immature hematopoietic cells, n the T cell depleted immature hematopoietic cells
comprise less than 5 x 105 CD3+ cells per kilogram body weight of the subject, and
wherein the dose comprises at least about 5 x 106 CD34+ cells per kilogram body
weight of the subject; and subsequently (c) administering to the subject a therapeutically
effective amount of cyclophosphamide, wherein the therapeutically effective amount
comprises 25-200 mg per kilogram body weight, thereby treating the subject.
2012/050542
According to an aspect of the present invention, there is provided a method of
inducing donor specific tolerance in a t in need of a ngeneic cell or tissue
graft, the method comprising: (a) transplanting into a t a dose of T cell depleted
immature hematopoietic cells obtained from a non—syngeneic donor, n the T cell
depleted immature hematopoietic cells comprise less than 5 X 105 CD3+ cells per
kilogram body weight of the subject, and wherein the dose comprises at least about 5 x
106 CD34+ cells per kilogram body weight of the subject; and subsequently (b)
administering to the subject a therapeutically effective amount of cyclophosphamide,
wherein the therapeutically effective amount comprises 25—200 mg per kilogram body
weight, thereby treating the t.
As used herein, the term “donor specific tolerance” as used herein refers to a
condition in which there is a decreased responsiveness of the recipient's cells (e.g.
recipient's T cells) when they come in t with the s cells (cg. donor
hematopoietic cells) as compared to the responsiveness of the recipient's cells in the
absence of such a treatment method.
Tolerance induction enables lantation of a cell or tissue graft (as described
in further detail hereinabove) with reduced risk of graft rejection or GVI—ID.
According to one embodiment of the present invention, patients with early
molecular and/or hematological e may receive donor lymphocyte infusions (DLI).
According to one embodiment of the present invention, DLI may comprise 1 x
103 - 1 x 106 CD3+ T cell/Kg recipient body weight.
According to one embodiment, patients with early molecular and/or
hematological relapse may receive a single dose or several doses (two, three, four, five
or more doses) of DLI.
Thus, for example. patients with early molecular and/or hematological relapse
may receive a first dose of l x 104 CD3“ T cell/Kg recipient body weight. In the
absence of graft versus host disease (GVHD), a second infusion of l x 105 CD3+ T
cell/kg recipient body weight may be given e. g. 45 days later followed e.g. 2 months
later by a third dose of l x 106 CD3+ T cell/kg recipient body weight.
According to one embodiment, patients with early molecular and/or
logical relapse may receive total body irradiation (TBI), total id
irradiation (TLI), a chemotherapeutic agent and/or an antibody immunotherapy.
Thus, for e, patients with relapsing B cell non—Hodgkin lymphoma may
receive rituximab (e.g. at a dose of 375 mg/m2 weekly) for about 4 weeks with DLI
concomitant with the second rituximab dose.
Thus, for example, patients with relapsing multiple myeloma may be treated
with bortezomib (eg. at a dose of 1.3 mg/sqm on days 1, 4, 8 and 11) before starting
DLI.
As used herein the term “about” refers to i 10 %.
The terms ises", "comprising", ”includes", "including", “having” and
their conjugates mean "including but not limited to".
The term “consisting of means “including and limited to”.
The term ”consisting essentially of” means that the composition, method or
structure may include additional ingredients, steps and/or parts, but only if the
additional ingredients, steps and/0r parts do not materially alter the basic and novel
characteristics of the claimed composition, method or structure.
As used herein, the singular form ”a“, 'an” and "the" include plural references
unless the t clearly dictates ise. For example, the term "a compound" or
"at least one compound" may include a plurality of compounds, including mixtures
thereof.
Throughout this application, s embodiments of this invention may be
presented in a range format. It should be understood that the ption in range format
is merely for convenience and brevity and should not be ued as an inflexible
limitation on the scope of the invention. Accordingly, the description of a range should
be considered to have specifically sed all the possible subranges as well as
individual numerical values within that range. For e, description of a range such
as from 1 to 6 should be considered to have specifically disclosed subranges such as
from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well
as individual numbers Within that range, for example, 1, 2, 3, 4, 5, and 6. This applies
regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited
numeral (fractional 0r integral) within the indicated range. The phrases “ranging/ranges
between” a first indicate number and a second indicate number and “ranging/ranges
from” ‘9
a first indicate number “to‘ a second indicate number are used herein
interchangeably and are meant to include the first and second indicated numbers and all
the fractional and integral numerals etween.
As used herein the term "method" refers to manners, means, techniques and
procedures for accomplishing a given task including, but not limited to, those manners,
means, techniques and procedures either known to, or readily developed from known
manners, means, techniques and procedures by practitioners of the chemical,
pharmacological, ical, biochemical and medical arts.
It is appreciated that certain features of the invention, which are, for clarity,
described in the context of separate embodiments, may also be provided in combination
in a single embodiment. Conversely, various features of the ion, which are, for
brevity, described in the context of a single embodiment, may also be provided
separately or in any suitable subcombination or as suitable in any other described
embodiment of the invention. Certain features described in the context of various
ments are not to be considered essential features of those ments, unless
the ment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated
above and as claimed in the claims section below find experimental support in the
following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above
ptions, illustrate the invention in a non limiting fashion.
lly, the nomenclature used herein and the tory procedures utilized
in the present invention include molecular, biochemical, microbiological and
recombinant DNA techniques. Such techniques are thoroughly explained in the
literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et
al., ; "Current Protocols in Molecular y" Volumes I—Ill Ausubel, R. M., ed.
; Ausubel et al., "Current Protocols in Molecular Biology”, John Wiley and Sons,
Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John
Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", ific
American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory
Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998);
methodologies as set forth in US. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659
and 5,272,057; ”Cell y: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed.
(1994); ”Current Protocols in Immunology" Volumes 1-111 Coligan 1. 13., ed. (1994);
Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange,
Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected s in Cellular
Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are
ively bed in the patent and scientific ture, see, for example, US. Pat.
Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 219;
5,011,771 and 5,281,521; ”Oligonucleotide Synthesis” Gait, M. 1., ed. ; “Nucleic
Acid Hybridization” Hames, B. D., and Higgins S. 1., eds. (1985); "Transcription and
Translation" Hames, B. D., and Higgins S. 1., Eds. (1984); "Animal Cell Culture”
Freshney, R. 1., ed. ; ”Immobilized Cells and Enzymes" IRL Press, ; "A
Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in
Enzymology" Vol. 1—317, Academic Press; "PCR Protocols: A Guide To Methods And
Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for
Protein Purification and Characterization — A Laboratory Course " CSHL Press
(1996); all of which are incorporated by reference as if fully set forth herein. Other
l references are provided throughout this document. The procedures therein are
believed to be well known in the art and are provided for the convenience of the reader.
All the information contained therein is incorporated herein by reference.
EXAMPLE 1
Stable engraflment ofHLA mismatched bone marrow following transplantation of
'mega dose’ bone marrow andpost transplantation cyclophosphamide
MATERIALS AND EXPERIMENTAL PROCEDURES
Animals
Mice used in these studies were 6-12 week old female mice. Balbfc—Nude (H-2d)
and C3H/Hen (H—2k) were purchased from Harlan Israel (Rehovot, Israel). All mice
were kept in small cages (5 animals in each cage) and fed sterile food and acid water.
These studies were approved by the Weizmann Institute of Science, Institutional
Animal Care and Use Committee.
Transplantation protocol
Low (5 x 106) and high dose (25 x 106) Balb/c—Nude BM cells (providing a
U: source of BM depleted of T cells) were transplanted into neic recipients
en) on day 0 following in—vivo T cell debulking (TCD) with anti—CD4 (clone
GK1.5) and anti—CD8 (clone 53.6.72) dies (300 pg each; Bio X Cell, NH, USA)
red on day —6, and exposure to 2.0 Gy total body ation (TBI) on day —1.
High dose hosphamide (CY, 100 mg/kg, Baxter Oncology, Germany) was
administered on days +3 and +4 post transplant and donor type chimerism was
evaluated 35 and 95 days post transplant using fluorescein anti-host and donor H—2
antibodies (e.g. FlTC labeled anti—l—l-2Dd antibody specific for donor type cells and PE
labeled anti-H-ZKk antibody c for host type cells).
Skin graft ol
Donor (Balb/c) and 3rd party (C57BU6) skin grafts were transplanted to the
mixed chimeric recipients as bed above [i.e. to those mice which were previously
transplanted with mega dose (25 x 106) T cell depleted EM and were treated with high
dose CY] and to the recipient mice that were inoculated with a regular (5 x 106) T cell
depleted BM cell dose and were treated with high dose CY.
RESULTS
To test the potential synergy between “mega dose’ T cell depleted bone marrow
transplant (BMT) and high dose cyclophosphamide (CY) post transplant, after reduced
intensity conditioning (RIC) of the recipient mice, the following experiments were
carried out.
Recipient mice (C3H/Hen) were treated with a conditioning protocol prior to
transplantation of a T cell depleted bone marrow transplant. Specifically, mice were in—
vivo treated with T cell debulking (TCD) using anti—CD4 and anti—CD8 antibodies
delivered on day -6 and by exposure to 2.0 Gy total body irradiation (TBI) on day ~l.
Next, low (5 x 106) or high dose (25 x 106) Balb/c—Nude BM cells (providing a source of
BM depleted of T cells, as Nude mice have miniscule numbers of mature T cells) were
transplanted into allogeneic recipients (C3H/Hen) on day 0. High dose
cyclophosphamide (CY, lOO mg/kg) was administered on days +3 and +4 post
transplant. Evaluation of bone marrow cell engraftment was evaluated by donor type
chimerism at 35 and 95 days post transplant.
As shown in Figures lA—B and Figures 2A-B, chimerism analysis on day 35 and
day 95 ed that none of the control mice (conditioned with TCD, 2 Gy TBI and
optionally CY, but did not receive BM) expressed donor type chimerism. Similarly,
none of the BM mice recipients that were transplanted with a regular dose of 5 x 106 T
cell depleted BM, in the ce or absence of cyclophosphamide treatment, expressed
donor type chimeiism. However when the dose of T cell ed BM was increased to
x 106 cells, durable mix chimerisrn was achieved in 4 out of 7 mice that were also
treated with cyclophosphamide on days +3 and +4 post lant (see Figures lA-B
and Figure 2C).
Further follow-up of these recipient mice at 180 and 225 days post transplant
revealed that the chimeiism induced was stable and e (Figure 3). As illustrated in
Figure 3, the number of donor type chimeric recipients and the level of donor chimeiism
remained unchanged 225 days post transplant, suggesting that tolerance has been
achieved.
nce induction was measured by transplantation of donor (Balb/c) and 3rd
party (C57BL/6) skin grafts to the mixed chimeric recipients that were transplanted with
mega dose (‘25 x 106) T cell depleted BM and were treated with high dose CY (as
2O described above), in comparison to the ents that were inoculated with a regular (5
x 106) T cell depleted BM cell dose (as described above).
As shown in Figures 4A~B, three out of 4 chimeric mice that were transplanted
with 25 x 106 T cell depleted BM accepted the donor graft and rejected the 3rd party skin
grafts. In contrast, recipient mice that were inoculated with 5 X 106 T cell depleted BM
cells and CY rejected both the donor and 3rd party skin grafts e 4A).
These results illustrate that the combination of mega dose T cell depleted BM
and high dose Cyclophosphamide treatment allows the successful engraftment of
hematopoietic stem cells, under reduced intensity conditioning, along with tolerance
ion.
Encouraged by these s a set of calibration ments were initiated in
order to determine the Optimal irradiation and Cyclophosphamide dose to improve
chimerism induction by this approach.
WO 93920
EXAMPLE 2
The efiect ofdifferent doses of total body ation (TBI) on chimerism
MATERIALS AND EXPERIMENTAL PROCEDURES
Animals
As described in Example 1, hereinabove.
Transplantation ol
High dose (25 x 106) Balb/c—Nude BM cells (providing a source of BM depleted
of T cells) were transplanted into allogeneic recipients (C3l-l/l-len) on day 0 following
in—vivo T cell ing (TCD) with anti-CD4 (clone GK1.5) and anti—CD8 (clone
53.6.72) antibodies (300 5.1g each; Bio X Cell, NH, USA) delivered on day —6, and
exposure to different doses of irradiation ranging from 1 to 3.5 Gy TBI on day -1. High
dose Cyclophosphamide (CY, 100 mg/kg, Baxter Oncology, Germany) was
administered on days +3 and +4 post transplant and donor type chimerism was
evaluated 30 days post transplant using fluorescein anti~host and donor H—2 antibodies
(eg. FITC labeled anti—H-ZDd antibody specific for donor type cells and PE labeled
anti—H—ZKk dy specific for host type cells).
RESULTS
In this experiment, the minimal irradiation dose was defined. ‘Mega dose’ (25 x
106) —Nude T cell depleted BM was transplanted into 5 groups of allogeneic
recipients (C3H/Hen) on day 0 following T cell debulking (with anti-CD4 and anti—CD8
antibodies) on day —6, and different doses of irradiation (ranging from 1 to 3.5 Gy TBI)
on day ~1. High dose Cyclophosphamide (CY) was administered on days +3 and +4
post transplant and donor type chimerism was ted at 30 days post transplant.
As can be seen in Figure 5, all the recipient mice that were ated with 2.5, 3
or 3.5 Gy TBI (6/6) were ic, exhibiting donor type chimerism ranging between
58 — 83 %. Similarly, 87 % ) of the mice treated with 2 Gy TBI exhibited donor
type chimeiism ranging between 56 - 85 %.
Further reduction of the irradiation dose to 1.0 Gy caused a small reduction in
the percentage of chimeric mice, namely 83 % (5/6), however the donor type chimerism
range was significantly reduced to 14.5 — 58 %.
EXAMPLE 3
The efiect of ent Cyclophosphamide (CY) doses on chimerism
MATERIALS AND EXPERIMENTAL PROCEDURES
Animals
As described in Example 1, hereinabove.
Transplantation protocol
High dose (25 X 106) Balb/C~Nude BM cells ding a source of BM depleted
of T cells) were lanted into allogeneic recipients (CSH/Hen) on day 0 following
in—vivo T cell debulking (TCD) with anti—CD4 (clone GK1.5) and anti—CD8 (clone
53.6.72) antibodies (300 ug each; Bio X Cell, NH, USA) delivered on day —6, and
exposure to 2.0 Gy total body irradiation (TBI) on day —l. Different doses of
Cyclophosphamide (CY, 100 mg/kg, 125 mg/kg or 150 rug/kg, Baxter gy,
Germany) were administered on days +3 and +4 post transplant and donor type
chimerism was evaluated 30 days post lant using fluorescein anti—host and donor
H-2 antibodies (e.g. FlTC labeled anti-H—2Dd antibody specific for donor type cells and
PE labeled anti-H-2Kk antibody specific for host type cells).
RESULTS
In this experiment, the optimal dose of CY post transplant was defined. ‘Mega
dose’ (25 x 106) Balb/c—Nude BM cells were transplanted into 3 groups of allogeneic
ents (C3H/Hen) on day 0 following T cell debulking (TCD) with anti—CD4 and
anti—CD8 antibodies on day -6, and 2 Gy TBl on day -1. Different doses of
Cyclophospharnide (CY), 100 mg/kg, 125 mg/kg or 150 nag/kg, were administered on
days +3 and +4 post transplant and donor type chimerism was performed 30 days post
transplant.
As can be seen in Figure 6, increasing CY dose to 125 mg/kg or 150 mg/kg did
not provide a significant enhancement of chimeiism. Thus, the recipient mice that were
d with 100 tug/kg, 125 mg/kg or 150 nag/kg CY exhibited an average of 57.5 i
.8, 66.5 i 20.6 or 67.4 i 27.4 donor type chimerism, tively. No statistical
icance was found when the recipients treated with 100 mg/kg were compared to
those treated with 125 mg/kg or 150 mg/kg (P=O.5 and p=0.469 respectively).
EXAMPLE 4
C08+ Non-T cells are not importantfor attaining chimerism by combining ‘mega
dose’ T cell depleted BM with CYpost transplant
MATERIALS AND EXPERIMENTAL PROCEDURES
Animals
As bed in Example 1, hereinabove.
Transplantation protocol
High dose (25 x 106) of CD8 depleted and non-depleted Balb/c—Nude BM cells
were transplanted into 2 cohorts of allogeneic recipients (C3H/Hen) on day 0 following
in~vivo T cell debulking (TCD) with anti-CD4 (clone GK1.5) and anti-CD8 (clone
53.6.72) antibodies (300 ug each; Bio X Cell, NH, USA) delivered on day -6, and
exposure to 2.0 Gy total body irradiation (TBI) on day —1. High dose
Cyclophosphamide (CY, 100 , Baxter Oncology, Germany) was administered on
days +3 and +4 post lant and donor type chimeiism was evaluated 30 days post
transplant using fluorescein anti-host and donor H-Z antibodies (e. g. FITC labeled anti-
H-2Dd antibody specific for donor type cells and PE labeled anti—H-2Kk antibody
specific for host type cells).
The BM source in these experiments was —Nude mice. Moreover, the
lanted mice in these experiments were athyrnic and as such they lacked T cells.
However in order to refute the possibility that the effect was a contribution of residual
non—T CD8 cells, the BM ation from Balb/c—Nude mice was vely sorted for
CD8 cells using a cell sorting system (e. g. anti—CD8 magnetic beads or FACS sorter).
As Ildstad et al. previously taught that a subset of CDSJr TCR‘ BM cells are
critical for achieving donor type chimerism [Fugier-Vivier I] et al., J Exp Med (2005)
201:373-383; Grimes HL et al., Exp Hematol. (2004) 32:946—954; Huang Y et al., Blood
(2011) 117:2494-2505; Kaufman CL et al., Blood (1994) 84:2436-2446; Leventhal J et
al., BMC Med (2012) 10:48; Leventhal J et al., Sci Trans! Med. (2012) 4:1241‘al28], the
present inventors ed residual CD8+ cells from the ——Nude ‘mega dose’ BM
preparation, and measured chimerism induction compared to control non-CD8+ depleted
Nude BM cells.
As can be seen in Figure 7, ion of CD8+ T cells from the BM preparation
did not have any adverse impact on the level of chimeiism achieved when combing
‘mega dose’ T cell ed BM cells with post transplant CY.
EXAMPLE 5
Clinical protocol
STUDY DESIGN
This is a prospective, observational, phase l/ll multicenter study. Ten patients
with logical disorders will be enrolled over a one year period.
The primary endpoint of the study is engraftment and 10 evaluable patients (i.e.
patients surviving beyond day 28) will be entered. An acceptable primary graft failure
or rejection rate is approximately 10 %.
Sludv duration
The primary analysis will be conducted using 6 and 12 months follow—up data.
Patients will be followed—up until 48 months after lantation.
Definitions
Stable sustained engraftment is defined as phils, more than lOOO/ul for
three consecutive days, and ets, more than ZOOOO/ul for three consecutive days,
2O without transfusion.
Graft rejection is d as rapid decline of neutrophils, less than lOO/nl after
documented neutrophil engraftment, with or without increase of lymphocytes.
Graft failure is defined as failure to reach more than l neutrophils for
three consecutive days and more than 20000/lll platelets for three consecutive days
without transfusion at day +28.
The secondary endpoint of the study is the incidence of grade II—IV acute
GVHD. An acceptable incidence of grade II~lV acute GVHD is approximately 10 %.
For acute GVHD grading criteria is indicated in Tables lA—B, below.
Table 1A: Clinical g of acute GVHD
SKIN LIVER GUT
Rash more than 25 % Bilirubin = 2—3 mg/dl Diarrhea 500- 1000 ml
Rash 25-50 % Bilirubin = 3—6 mg/dl Diarrhea 1000—1500 n11
Generalized Diarrhea more than 1500
Bilirubin = 6-15 mg/dl
erythroderrna ml
Desquamation and Bilirubin more than 15
Pain or ileus
bullae mg/dl
Table 1B: Clinical grading of acute GVHD
++ to +++
IV / life
ening ++ to ++++ ++ to ++++
Statistical considerations
The time intervals for tment, survival, disease-free survival, relapse rate
and risk of transplant—related mortality will be calculated from the day of stem cell
transplantation. Actuarial curves will be ated according to the Kaplan—Meier
method.
ELIGIBILITY CRITERIA
Inclusion Criteria - Patient
— Age ~ more or equal to 18 and less or equal to 70 years old
— CLL patients with toriness to fludarabine or other chemotherapy
due to the p53 loss by 17p deletion and/or TP53 mutation
- Follicular lymphoma with either unfavorable cytogenetics such as
complex karyotype, dell7p, del 6q23-26, mutations in TP53, minus 1p
— Hodgkin's Lymphoma relapsed after autologous transplantation, not
eligible for immunotherapy with anti-CD30
— Multiple myeloma relapsing after gous lantation, with
rable cytogenetics in either partial or complete remission
- Severe Aplastic Anemia relapsing after immunotherapy
— Absence of fully HLA-matched or one locus HLA—mismatched family
donor
— Absence of matched unrelated donor or ineligibility for donor search in
the donor registry (lBMDR)
— Presence of haploidentical family donor and a back—up of patient
gous stem cells
- Stable clinical ions and life expectancy of more than 12 weeks
— Karnofsky — more than 70 ‘70
— Written informed consent
Pre-treatment tion
— complete clinical history and examination and determination of
mance status and body surface area.
- complete blood count
— blood group, red blood cells subgroups, anti~A and/or anti—B agglutinin
titration
— creatinine nce, uric acid, ferritin, LDH, beta 2 microglobulin,
protein electrophoresis, SGOT, SGPT, urine test, blood glucose, blood nitrogen,
immunoglobulin levels, Coombs tests.
— pregnancy test
— HIV-ab, HBsAg, HBVDNA, HCV—ab, HCVRNA, CMV—ab,
Toxoplasma~ab, HSVab
— ECG and measurement of ejection fraction by ultrasound or scintigraphic
tCSt.
- chest X ray.
— lung CT scan, brain CT scan, maxillary sinus CT scan.
- dental X ray and examination.
— biopsy and bone marrow aspirate for morphologic and cytogenetic
analysis, search for a lar marker (if not known) and FACS analysis
(according to underlying disease).
— neurologic examination and lumbar puncture in patient at risk.
- radiologic scan (CT, NMR) of the known disease localization.
~ complete serologic and molecular HLA typing, ML cultures and
cytotoxicity test with the selected donors.
— cytotoxic anti HLA antibodies.
- Abdominal echography
IO Exclusion criteria - Patient
— History of central nervous system disease localization
— Positivity for HIV, HCV, HCVRNA, HBsAg, HBVDNA
— Active and documented nia of any kind, fungal tissue infection,
viral positive cultures of respiratory secretion or blood
- bilirubin of more than 2 times normal
- blood creatinine nce less than 50 ml/min
- DLCO less than 50 % of the predicted value
— ejection fraction less than 45 % (or myocardial stroke in the last year)
— pregnancy or lactation
— psychiatric disorders
Eligibility Criteria - Donor
~ Absence of poietic or marrow function related disease that
interferes with the collection of sufficient numbers of normal progenitor cells.
- e of any medical condition that would pose a serious health risk
by undergoing peripheral blood stem cell harvest
~ Negative HIV, HTLV—l tests
- Any healthy family member will be considered for hematopoietic stem
cell donation. Selection of a donor will be based on typing of HLA-A, B, C, DR
loci to be carried out on the recipient, siblings, parents and ly other family
members such as aunts, uncles and cousins. A prospective d donor must be
at least genotypically HLA-A, B, C, DR haploidentical to the patient, but can
differ for 2-3 HLA alleles on the ed haplotype.
2012/050542
- Donor will be selected preferentially on the basis of the donor—versus—
recipient NK alloreactivity.
Donor Evaluation
— te history, physical examination and examination of physical
veins by the pheresis service for determination of suitability for pheresis via
eral veins.
- Blood tests: WBC, FLT, Hb, PT, PTT, total n, albumin,
electrolytes, glucose, SGOT/SGPT. alkaline phosphatase, bilirubin, LDH, acid
uric, creatinine.
— CMV, EBV, HSV, VZV, Hepatitis B + C, HIV, Toxoplasma serology.
— Complete red blood cell typing
— Serology for Syphilis, CMV, EBV, HSV, VZV, Hepatitis B + C, HTLV—
1, HIV, Toxoplasmosis.
— Transfusion transmitted disease g must be performed between 30
and 7 days prior to stem cell collection
— Chest X-ray
- EKG
- VNTR analysis by PCR
— Donors will be piioritized on the basis of r age, better health, and
being CMV~negative for CMV—negative recipients.
Exclusion Criteria — Donor
~ A positive HIV or HTLV—l test or evidence of active/persistent viral
hepatitis infection will exclude the donor from participation in this study.
— ce of any medical condition that would pose a serious health risk
by undergoing peripheral biood stem cell harvest (i.e. insulin—dependent
diabetes, cardiovascular disorders, chronic inflammatory diseases).
TREATMENT PROCEDURES
Mobilization of donor HSC and Graft processing.
Patients are required to have a family donor (aged 18 to 60 yrs), g and
e of donating filgrastim/lenogastrim-stimulated peripheral blood hematopoietic
cells. Donors will be screened according to Blood Bank general miles. It is advisable to
perform an se EKG testing in donors above 50 yrs of age. Normal donors will
receive filgrastim or lenogastrim 5 meg/kg subcutaneously every 12 hours; on day 5 the
leukapheresis will be started. Filgrastim/Lenogastrim dosage will be adjusted to
maintain white blood cells below 60 x 109/L. On the 4th day of filgrastim/lenograstim
treatment, if the circulating CD34+ cell count is more than 40/uL, the donor will start
leukapheresis. Daily leukapheresis will be continued for a planned 3 days, with a
maximum of 4 days, to collect a target cell dose of more than 10 x 106 CD34+ cells/kg.
If the target is reached early, collection can continue for 3 total days in order to give the
largest possible dose. If the donor does not tolerate the procedure in any of its
component parts, an alternative donor may be used if available. If a site is unable to
t more than 10 x 106 CD34+ cells/kg from an appropriate donor, ts may not
d on study. PBPCs will be depleted of donor T and B cells by selection of CD3+
and/or CD19+ cells using a cell sorting system (cg. anti-CD3/l9 magnetic beads or
FACS sorter). Target value of CD34-positive cells will be at least 10 x 106/kg of the
recipient body weight (b.w.).
The apheresis will be med through the antecubital veins.
Table 2: Conditioning regimen
day -7 i Fludarabine 301ng/sqm
day 6 E Fludarabine 30mg/sq1n
day -5 E Fludarabine 3O mg/sqm
day 4 l Fludarabinc 30 mg/sqm
day —3 Fludarabine 3O mg/sqm
day -2 § TBI 2 Gy single fraction
day -l l Rest
day 0 l Graft
day +1 l Rest
day +2 l Rest
day +3 ; CY 50 rug/kg
day +4 I CY 50 trig/kg
As described in Table 2, above, fludarabine will be administered intravenously
daily on 5 sequential days, -7, -6, -5, —4, and —3, at a dose of 30 mg/m2. Each dose will
be d over 30 s. TBI 200 cGy will be given on day —l in a single fraction.
On day 0, CD3'/CD19' immunoselected HSCs will be thawed, washed and
infused h a central access.
CY will be administered intravenously in one hour on days +3 and +4 post—
transplantation at 50 mg/kg/day.
Special management orders
a. a double—lumen central venous line will be placed before conditioning
regimen;
b. for urate prophylaxis allopurinol 300 mg per 08 will be given;
c. antiemetic therapy will be given according to single center guidelines;
d. transfusion of filtered and irradiated blood products. Keep hemoglobin
level more than 8 g/L and platelets more than 15000/ ttL in absence of fever or bleeding
signs;
Patient monitoring during treatment
a. daily full blood count and ential
b. serum nine, Na+, K+, Ca++, bilirubin daily during chemotherapy
and hyper-hydration
c. liver function tests, albumin, coagulation tests with antitrombin III,
cytomegalovirus nemia and PCR twice a week.
d. surveillance cultures according to center guidelines
TOXICITY EVALUATION
Toxicity will be ted according to WHO criteria, as indicated in Table 3,
below.
Table 3: WHO toxicity criteria
—GradeO Grade 1
-_——
2 11.0
g/dl 95—109 g/dl 4 g/dl 6.5~7.9 g/dl < 6.5 g/dl
Hen10g 01 bin
2 6-8 5.6-6.7 mmol/l 4.9—5.6 mmol/l 4.0-4.9 mmol/l < 4.0 mmol/l
mmol/l
ytes
2 4-0 339 2.0 2 9 1.0—1.9
(IOOOfmm)
Granulocytes
2 2.0 1.5—1.9 l 0—1.4 0.5-0.9 < 0 5
(1000/mm)
Platelets (lOOO/unn) 2 100 75—99 50-74 25—49
PCTlIL2012/050542
Mild blood Gross blood
Hemorrhage Petechiae Debilitating
loss loss blood loss
Gastrointestinal
Transaminases
126—25 X N*
(SGOT SGP’T)
Alkaline
1.26~2.5 X N*
otase
Erythema, Ulcers :
Soreness/ Alimentation
NO change ulcers: can eat requires liquid
erythema not possible
solids diet onl
Transient Vomiting
lntractable
/vomiting requiring
vomiting
therav vomiting
Intolerable.
Transient < 2 Tolerable, but
Diarrhoea Hemorrhagic
requiring
ation
Blood urea or $1.25X
126m5xNn 2%:
creatinine Ny
1+ 23+
Proteinuria No change < 0.3 g % Nephrotic
0&10g%
< 3 g/l 340 0/1 syndrome
Obstructive
Heinaturia No change Microscopic Gross + clots
uro - ath_
Mild onal Complete
Pulmonary No change Dyspnoea at
bed rest
symptoms ea rest
re 0 uired
Fever with drug None Fever < 38 °C Fever 38-40 ° Fever > 40 “C
h notenswn
Bronchospasm:
Bronchospas
No change Oedema parenteral
: no parenteral Anaphylaxis
therapy
therapy neede
re uired
Exfoliative
Dry dermatitis:
Most
Cutaneous necrOSis
No change Erythema mation,
desquamation,.
vesiculation, . .
ulceration. reqmring
pruritus surgical.
intervention
Moderate, Complete Non-
Minimal hair
No change patchy
loss alopecia but reversible
alo n ecia reversible alo ecia
Major
with
Infection (specify Minor Moderate
None Major
site) infection. , infection infection hypotension
Sinus Unifocal PVC
Multifocal Ventricular
Rhythm tachycardia, atrial
arrh thmia tachycardia
> 110 at rest
Transient . Symptomatic
Asymptomatic,. . Symptomatic
matic ,
. dysfunction
Function. but abnormal . ction
dysfunction: . non-
cardiac s1gn. . swe to .
no therapy responsive to
. therapy
re urred
thera .
Tamponade:
Pericarditis No change Asymptomatic Symptomatic: Tamponade:
effusron. . . surgery
no tap require tap ed
re uired
State of Transient
. 50 % of Coma
conscrousness therapy
waking hours
Paresthesias Severe Intolerable
and or hesias paresthesias
Peripheral
decreased and or mild and or marked Paralysis
tendon reflexe weakness motor loss
Constipation. . xx Abdominal Distension
- Moderate.
distenSion. . and vomitino. .
Pain Moderate Intractable
N* upper limit of normal value of population under study.
** This does not include constipation resultant from narcotics
+ Only treatment-related pain is considered, not disease-related pain.
UI Use of narcotics may be helpful in grading pain ing on the patient's tolerance.
SUPPORTIVE CARE
Monitoring and treatment of bacterial and fungal infections
ts are cared for in isolation rooms with laminar airflow or fficiency
air-particulate filtration. Liposomal Amphotericin is given at 1 mg/kg/day from day —5
to engraftment as antifungal prophylaxis. Bacterial infections are monitored by swabs
and blood es . Intravenous otic therapy is started on the basis of
clinical signs of infection (fever of unknown origin) or positive blood cultures. If the
patient is still febrile after 72 hours, empiric antifungal therapy is started using either L—
AMB 3 mg/kg/day or Voriconazole 8 mg/kg/day i.v. Vancomycin is added after an
additional 72 hours of fever, or in the presence of Gram+ sepsis, or positive blood
culture.
Prophylaxis, ring and treatment of cytomegalovirus infections
In recipients who are seropositive for CMV antibody, CMV prophylaxis consists
of ganciclovir (10 mg/kg/day) between the tenth and second day before stem cell
on. Ganciclovir is oduced as preemptive therapy from day +21 until day
+360. CMV antigenemia/PCR is determined weekly in blood samples. If CMV
antigenemiaJPCR develops, patients will treated with ganciclovir (10 mg/kg/day) or
foscarnet (180 mg/kg/day).
The blood products are irradiated (30 Gy) before transfusion.
Post-Transplant Laboratory Evaluation:
1. Daily te hemograms until granulocytes and platelets are self—
sustaining, then three times/week until discharge; at least every week post discharge to
day 100 and then every 2 weeks to 12 months.
2. ing profile with liver and renal function tests twice weekly for the
first 30 days, then weekly to discharge; more frequently if clinically indicated.
3. Bone marrow aspirates for morphology analysis of chimerism by FISH
(sex—mismatched grafts) or cytogenetics will be done at approximately 1, 3, 6, 12
months, and every 4 months thereafter for approximately 3 years. onal analysis
will be done as clinically indicated. Patients with CML will be also monitored for
bcr/abl evidence of recurrence
4. Immunological reconstitution will be monitored by in vitro assays,
including ypic analysis of ating lymphocytes, assessment of natural killer
and lymphokine activated killer cell function, lymphocyte transformation responses to
T-cell and B—cell mitogens and immuneglobulin levels.
Follow-up
Until day +90 complete blood counts, nemia and PCR for CMV, reactive
protein C, complete liver and renal function will be assess twice a week.
Every two weeks until +90 peripheral blood phenotype (CD3, CD4, CD8,
CD19, CD56, CD57, HLADR), chest Xi'ay.
Every two weeks from +90 till +180:
complete blood counts, antigenemia and PCR for CMV, reactive protein C,
complete liver and renal function.
Monthly:
immunoglobulin , n electrophoresis,
after +90 peripheral blood phenotype (CD3, CD4, CD8, CD19, CD56, CD57,
HLADR), chest Xray.
after + 180 complete blood counts, antigenemia and PCR for CMV, reactive
protein C, complete liver and renal on.
Complete restaging of disease will be performed 2, 4, 6, 8, l2, l8 and 24 months
after transplantation then annually, this will include assessment of donor chimerism by
PCR analysis of HLA on eral blood and bone marrow cells.
For Performance Status grading criteria see Table 4, below.
Table 4: Karnofsky Performance scale
FUNCTIONAL STATUS GROUP SCORES
Normal. No complaints. No ce of disease.
Able to carry on normal ty. Minor signs or
symptoms of e. Rehabilitated
Normal activity with effort. Some signs or symptoms (80+)
of disease.
Cares for self. Unable to carry on normal ty or Self-care only
do active work. (70-90)
Requires occasional assistance, but able to care for
most needs.
Requires considerable assistance and frequent medical Requires Caretaker
care. (40-69)
Disabled. Requires special care and assistance.
Severely disabled. Hospitalisation is indicated,
although death is not imminent.
Very sick, Hospitalisation ary. 2O
institutionalisation
Moribund. Fatal processes progressing. 10
( 1-39)
Dead.
PROGRAMMED INFUSIONS of DONOR LYMPHOCYTES
Donor lymphocyte ons (DLls) are effective to treat relapses after
allogeneic HSCT. Nevertheless, the success of DLI has been limited to some extent by
the morbidity and mortality ated with GVHD. Graded doses of T—cells are less
likely to produce GVHD than a single large infusion and appear to be as effective to
induce remission [Dazzi, Szydlo et al., Blood, (2000) 96: 2712—6]. A recent dose
finding study has shown that l x 104 unmanipulated CD3+ lymphocyte/kg recipient b.w.
can be safely infused in patients who have received a T cell depleted haploidentical
transplantation [Lewalle P. et al. Bone Marrow Transplant (2002) 29 (suppl 2): S26,
0164a].
Patients with early lar and/0r hematological relapse will receive a first
dose of 1 x 104 CD3+ cell/Kg recipient b.w.; in the absence of GVHD, the second infusion
of 1 x 105 CD3+ cell/kg will be given 45 days later followed 2 months later by a third
dose of 1 X 106 CD3+ g. Donors will undergo a leukoapheresis to collect
lymphocytes prior to mobilization of hematopoietic cells because it has been shown that
G—CSF has an immune—modulatory effect on some T cyte subsets, decreasing
their responsiveness to allogeneic stimuli. The frozen products will be thawed and
d y over a period of 5—10 minutes. Patients with acute GVHD or who fail to
demonstrate hematological tment will not receive any DLI.
Patients with relapsing B cell non-Hodgkin lymphoma will receive rituximab 375
mg/m2 weekly for 4 weeks with DLI concomitant with the second rituximab dose.
Patients with relapsing multiple myeloma will be treated with bortezomib (1.3 mg/sqm
on days 1, 4, 8 and 11) before starting DLI.
No LI immunosuppressive agents will be used
gh the invention has been described in conjunction with specific
embodiments thereof, it is evident that many alternatives, modifications and variations
will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such
alternatives, modifications and variations that fall within the range and broad scope of the
appended claims.
All publications, patents and patent applications ned in this specification are
herein incorporated in their entirety by into the cation, to the same extent as if each
individual publication, patent or patent application was specifically and individually
indicated to be incorporated herein by reference. In addition, citation or identification of
any reference in this application shall not be construed as an admission that such reference
is available as prior art to the present invention. To the extent that section headings are
used, they should not be construed as necessarily limiting.
Claims (76)
1. Use of a dose of T cell depleted immature hematopoietic cells, wherein said T cell ed immature poietic cells comprise less than 5 x 105 CD3+ cells per kilogram body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per am body weight of the subject, and a therapeutically effective amount of cyclophosphamide, wherein said therapeutically effective amount ses 25~200 mg per kilogram body weight of the subject, and n said cyclophosphamide is for administration to the subject following transplantation of a cell or tissue graft, in the manufacture of a medicament for treating a subject in need of a non-syngeneic cell or tissue graft, wherein said subject has a malignant disease.
2. Use of a dose of T cell depleted immature hematopoietic cells, wherein said T cell depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ cells per kilogram body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject, and a therapeutically effective amount of hosphamide, wherein said therapeutically effective amount comprises 25—200 mg per kilogram body weight of the subject, and wherein said hosphamide is for administration to the subject following lantation of a cell or tissue graft, in the manufacture of a medicament for treating a subject in need of a non-syngeneic cell or tissue graft, wherein said subject has a non—malignant disease.
3. The use of claim 1 or 2, wherein the medicament is adapted for administration with a reduced intensity conditioning protocol.
4. The use of claim 1 or 2, wherein the medicament is adapted for stration with an in—vz’vo T cell debulking conditioning protocol.
5. The use of claim 1 or 2, wherein a dose of said T cell depleted immature hematopoietic cells comprises 5 - 40 X 106 CD34+ cells per kilogram body weight of the subject.
6. The use of claim 5, wherein a dose of said T cell depleted immature hematopoietic cells comprises at least about 10 x 106 CD34+ cells per kilogram body weight of the subject.
7. The use of claim 1 or 2, wherein said T cell depleted immature poietic cells are selected from the group consisting of T cell depleted bone marrow cells, T cell depleted G-CSF mobilized peripheral blood progenitor cells, T cell depleted cord blood, purified CD34+ cells attained by positive selection from bone marrow and/or from G-CSF mobilized peripheral blood progenitor cells, and o expanded CD34+ cells.
8. The use of claim 1 or 2, wherein said T cell depleted re hematopoietic cells comprise less than 1 x 106 CD8+ TCRoz/H cells per am body weight of the subject.
9. The use of claim 1 or 2, wherein said T cell depleted immature hematopoietic cells are obtained by T cell debulking.
10. The use of claim 9, wherein said T cell ing is effected by antibodies.
11. The use of claim 10, wherein said antibodies are selected from the group consisting of an anti-CD8 antibody, an anti—CD4 dy, an anti-CD3 antibody, an anti— CD2 antibody and an anti—TCRoz/B antibody.
12. The use of claim 1 or 2, wherein said immature hematopoietic cells are treated by B cell ing.
13. The use of claim 12, wherein said B cell debulking is effected by an anti— CD19 antibody or by anti-CD20 antibody.
14. The use of claim 1 or 2, n said T cell depleted immature hematopoietic cells are from a non-syngeneic donor.
15. The use of claim 14, wherein said non-syngeneic donor is allogeneic or xenogeneic with respect to the subject.
16. The use of claim 15, wherein said neic donor is selected from the group consisting of an HLA matched sibling, an HLA matched unrelated donor, an HLA haploidentical related donor and a donor displaying one or more disparate HLA determinants.
17. The use of claim 1 or 2, wherein the subject is a human t.
18. The use of claim 4, wherein said o T cell debulking is effected by antibodies.
19. The use of claim 18, wherein said antibodies comprise an anti-CD8 antibody, an anti—CD4 antibody, or both.
20. The use of claim 18, wherein said antibodies comprise anti-thymocyte globulin (ATG) antibodies, D52 antibodies or anti-CD3 (OKT3) dies.
21. The use of claim 3, wherein said reduced ity conditioning comprise a non-myeloablative conditioning.
22. The use of claim 21, wherein said non—myeloablative conditioning comprise at least one of a total body irradiation (TBI), a total lymphoid irradiation (TLI), a chemotherapeutic agent and/or an antibody immunotherapy.
23. The use of claim 22, wherein said TBI comprises a single or fractionated irradiation dose within the range of 1-7.5 Gy.
24. The use of claim 23, wherein said TBI comprises a single or fractionated irradiation dose Within the range of 1—3 .5 Gy.
25. The use of claim 22, wherein said chemotherapeutic agent comprises at least one of Busulfan, Fludarabine, Melphalan and Thiotepa.
26. The use of claim 22, wherein said antibody comprises at least one of an D52 antibody, an anti—thymocyte globulin (ATG) dy and anti-CD3 (OKT3) antibody.
27. The use of claim 1 or 2, wherein said concentration of said cyclophosphamide is about 100 — 200 mg per kg body weight of the subject.
28. The use of claim 27, wherein said concentration of said cyclophosphamide is about 100 mg per kg body weight of the subject.
29. The use of claim 1 or 2, wherein said cyclophosphamide is ed in a single dose.
30. The use of claim 1 or 2, wherein said cyclophosphamide is effected in two doses.
31. The use of claim 30, wherein each of said two doses comprises a concentration of about 50 mg per kg body weight of the subject.
32. The use of claim 30, wherein each of said two doses is for administration on days 3 and 4 ing said transplantation of said cell or tissue graft.
33. The use of claim 1 or 2, wherein said cell or tissue graft ses immature hematopoietic cells.
34. The use of claim 1 or 2, wherein said cell or tissue graft is ed from the group consisting of a liver, a pancreas, a , a kidney, a heart, a lung, a skin, an intestine and a lymphoid/hematopoietic tissue or organ.
35. The use of claim 34, wherein said cell or tissue graft is effected prior to, concomitantly with or following said dose of T cell depleted immature hematopoietic cells.
36. The use of claim 34, wherein said cell or tissue graft comprises a co— transplantation of several organs.
3?. The use of claim 1 or 2, wherein said cell or tissue graft and said T cell depleted immature poietic cells are from the same donor.
38. Use of a dose of T cell depleted immature hematopoietic cells, wherein said T cell depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ cells per kilogram body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject, and a therapeutically effective amount of cyclophosphamide, wherein said therapeutically effective amount ses 25—200 mg per kilogram body weight of the subject, and wherein said hosphamide is for administration to the subject following transplantation of immature hematopoietic cells in the manufacture of a medicament for treating a conditioned subject in need of an immature hematopoietic cell transplantation, and wherein said subject has a malignant disease .
39. Use of a dose of T cell depleted immature hematopoietic cells, n said T cell depleted re hematopoietic cells comprise less than 5 x 105 CD3+ cells per kilogram body weight of a subject, and wherein said dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the t, and a therapeutically ive amount of cyclophosphamide, wherein said therapeutically ive amount comprises 25-200 mg per kilogram body weight of the subject, and wherein said cyclophosphamide is for administration to the subject following transplantation of immature hematopoietic cells in the manufacture of a medicament for treating a conditioned subject in need of an immature hematopoietic cell transplantation, and wherein said subject has a non- ant disease .
40. The use of claim 38 or 39, wherein said conditioned subject has been conditioned under reduced intensity conditioning protocol.
41. The use of claim 40, wherein said reduced intensity conditioning protocol is effected 1—10 days prior to lantation of immature hematopoietic cells.
42. The use of claim 40, wherein said reduced intensity conditioning comprises a non-myeloablative ioning protocol.
43. The use of claim 42, wherein said non-myeloablative conditioning protocol comprises at least one of a total body irradiation (TBI), a total id irradiation (TLI), a herapeutic agent and/or an antibody immunotherapy.
44. The use of claim 43, wherein said TBI comprises a single or fractionated irradiation dose within the range of 1—7.5 Gy.
45. The use of claim 44, wherein said TBI comprises a single or fractionated irradiation dose within the range of 1—3.5 Gy.
46. The use of claim 43, wherein said chemotherapeutic agent comprises at least one of Busulfan, Fludarabine, Melphalan and Thiotepa.
47. The use of claim 43, wherein said antibody comprises at least one of an anti-CD52 dy, an anti-thymocyte globulin (ATG) antibody and D3 (OKT3) antibody.
48. The use of claim 38 or 39, wherein said conditioned subject has been conditioned with in—vivo T cell debulking.
49. The use of claim 48, wherein said in—vivo T cell debulking is effected 4-7 days prior to transplantation of immature hematopoietic cells.
50. The use of claim 48, n said in—vivo T cell ing is effected by dies.
51. The use of claim 50, wherein said antibodies comprise an anti—CD8 dy, an anti—CD4 antibody or both.
52. The use of claim 50, wherein said dies comprise anti-thymocyte globulin (ATG) antibodies, an anti-thymocyte globulin (ATG) antibody and anti-CD3 (OKT3) antibody.
53. The use of claim 38 or 39, wherein a dose of said T cell depleted immature hematopoietic cells comprises at least about 5 - 40 X 106 CD34+ cells per kilogram body weight of the subject.
54. The use of claim 53, wherein a dose of said T cell depleted immature hematopoietic cells comprises at least about 10 x 106 CD34+ cells per kilogram body weight of the subject.
55. The use of claim 38 or 39, wherein said T cell depleted immature hematopoietic cells are selected from the group consisting of T cell depleted bone marrow cells, T cell depleted G—CSF mobilized peripheral blood progenitor cells, T cell depleted cord blood, purified CD34+ cells attained by positive selection from bone mairow and/or from G-CSF mobilized peripheral blood itor cells, and o expanded CD34+ cells.
56. The use of claim 38 or 39, wherein said T cell depleted immature hematopoietic cells comprise less than 1 X 106 CD8+ TCROl/B’ cells per kilogram body weight of the subject.
57. The use of claim 38 or 39, wherein said T cell depleted immature hematopoietic cells are ed by T cell debulking.
58. The use of claim 57, wherein said T cell debulking is effected by antibodies.
59. The use of claim 58, wherein said dies are selected from the group consisting of an anti-CD8 antibody, an anti-CD4 antibody, an anti-CD3 antibody, an anti- CD2 antibody and an anti-TCRodfi antibody.
60. The use of claim 38 or 39, wherein said immature hematopoietic cells are treated by B cell debulking.
61. The use of claim 60, wherein said B cell debulking is effected by an anti- CD19 antibody or anti—CD20 antibody.
62. The use of claim 38 or 39, wherein said T cell depleted immature hematopoietic cells are from a non—syngeneic donor.
63. The use of claim 62, n said non-syngeneic donor is allogeneic or xenogeneic with respect to the subject.
64. The use of claim 38 or 39, wherein the subject is a human subject.
65. The use of claim 38 or 39, wherein said concentration of said cyclophosphamide is about 100 - 200 mg per kg body weight of the subject.
66. The use of claim 65, wherein said concentration of said cyclophosphamide is about 100 mg per kg body weight of the subject.
67. The use of claim 38 or 39, wherein said cyclophosphamide is effected in a single dose.
68. The use of claim 38 or 39, n said hosphamide is effected in two doses.
69. The use of claim 68, wherein each of said two doses comprises a concentration of about 50 mg per kg body weight of the subject.
70. The use of claim 68, wherein each of said two doses is for administration on days 3 and 4 following said transplantation of said cell immature hematopoietic cells.
71. The use of claim 1 or 38, wherein said malignant disease is a hematopoietic cancer.
72. The use of claim 71, wherein said hematopoietic cancer comprises a leukemia or lymphoma.
73. The use of claim 71, wherein said hematopoietic cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myelocytic ia (AML), acute nonlymphoblastic leukemia (ANLL), Chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Hodgkin's Lymphoma, non— n's Lymphoma, Extranodal natural killer/T-cell ma, ous T-cell lymphoma, Enteropathy type T-cell lymphoma, Angioimmunoblastic T—cell lymphoma, Anaplastic large -cell lymphoma, Subcutaneous panniculitis-like T—cell lymphoma, Unspecified T-cell lymphoma, Diffuse large B-cell lymphoma, B-cell chronic lymphocytic ia (B-CLL)/chronic lymphoid leukemia (CLL), Chronic lymphocytic leukemia/small lymphocytic ma, Extranodal marginal zone B-cell lymphomas - mucosa-associated lymphoid tissue lymphomas, Follicular lymphoma, Mantle cell lymphoma, Nodal marginal zone B—cell lymphoma, Burkitt lymphoma, Hairy cell leukemia, Primary central nervous system ma, Splenic marginal zone B-cell lymphoma, Lymphoplasmocytic lymphoma, y mediastinal B-cell lymphoma and multiple myeloma.
74. The use of claim 2 or 39, wherein said non-malignant disease is a genetic disease or disorder, an autoimmune disease or a metabolic er.
75. The use of claim 2 or 39, wherein said non-malignant disease is selected from the group consisting of sickle cells e, a congenital neutropenia, a thrombocytopenia, an aplastic anemia, a myelodysplastic syndrome, a monosomy 7, an osteopetrosis, a Gaucher’s e, a Hurler's disease, a metachromatic leukodystrophy, an adrenal ystrophy, a thalassemia, a congenital or genetically-detennined hematopoietic abnormality, lupus, autoimmune hepatitis, celiac disease, type I diabetes mellitus, Grave's disease, Guillain-Barr syndrome, Myasthenia , Rheumatoid arthritis, scleroderma and psoriasis.
76. The use of any one of claims 1 to 75, substantially as herein described with reference to any one of the Examples and/or
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/578,917 | 2011-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ627272A NZ627272A (en) | 2016-12-23 |
NZ627272B2 true NZ627272B2 (en) | 2017-03-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11497776B2 (en) | Combination therapy for a stable and long term engraftment | |
JP6449199B2 (en) | Human promoting cells and uses thereof | |
EP2297306B1 (en) | Human facilitating cells | |
NZ627272B2 (en) | A combination therapy for a stable and long term engraftment | |
NZ627272A (en) | A combination therapy for a stable and long term engraftment | |
US20100129329A1 (en) | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION | |
NZ627549B2 (en) | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion | |
NZ627549A (en) | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |